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Alkaloids containing the nitrogen atom in the bridgehead position of two rings, 
such as indolizidine, pyrrolizidine, and quinolizidine alkaloids, have a wide and varied 
distribution in nature. Some of these alkaloids demonstrate a broad range of 
pharmacological activities and have generated substantial synthetic interest. This thesis 
covers the total synthesis of novel tylophorine analogs called DCB 3503, DCB 3506, 
DCB 3507, DCB 3508, DCB 3509, and a derivative with a biotinylated chain attached to 
DCB 3506 for use as a biological probe. This thesis discusses the biological activity of 
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Chapter One: Synthesis of DCB 3503 
1.1 Statement of Problem 
The objective was to develop a scale-up synthesis of DCB 3503. The National 
Cancer Institute showed in its anticancer screen that DCB 3503 (a synthetic compound, 
Figure 1) had a potent growth inhibitory effect (GI50 ~ 10
-8 M). To evaluate its antitumor 
potential, synthesis and large scale preparation was required. 
 
Figure 1: Structure of  R1 = OH, R2 = H, R3,R4 = OMe DCB-3503 
                       R1 = H, R2 = H, R3,R4 = OMe Tylophorine 
R1,R4 = H, R2,R3 = OMe, Tylophora crebriflora 
 
This highly potent anticancer compound needed to be synthesized in scale-up 
conditions in order to do more biological analysis. This compound, DCB 3503, requires 
at least 10 steps that involve reactions such as Perkin condensation1, cyclization 
through oxidative couplings,18 diastereoselective reduction2, intramolecular Friedel–
Crafts cyclizations1,  hydrolysis, peptide bonds, alkylations1, and amino acid couplings. 
These reactions required specific temperatures and molecular equivalent. 
In the past, the synthesis of DCB 3503 took longer time to be synthesized and 
the final compound yield was approximately 40–50 mg, therefore, the synthetic route 





Tylophorine and its analogs are phenanthroindolizidine alkaloids.3,4 These 
natural compounds have been isolated primarily from the genera Cynanchum, 
Pergularia, and Tylophora in the Asclepiadaceae family, but they have also been 
reported from Hypoestes verticillaris (Acanthaceae), Cryptocarya phyllostemmon 
(Lauraceae), as well as Ficus hispida and Ficus septica (Moraceae).  
DCB 3503 is an analog of tylophorine  and has an added secondary alcohol 
moiety. Tylophorine is a pharmacologically active5 phenanthrolizidine alkaloid. It is the 
major constituent of the plant Tylophorica indica (Asclepiadaceae). Its common names 
are anthrapachaka (Sanskrit), country ipecac, and Indian ipecac, and it is a perennial 
plant native to southern and eastern India.  
Tylophorine has medicinal properties. It has been proved to have antitumor 
activity,6 such as in breast cancer.2,7-9 It is an effective drug for bronchial asthma. This 
plant is used to treat respiratory diseases. It is useful as a bronchodilator, an emetic, 
and an expectorant. A similar compound from Tylophora crebriflora shows high activity 
against leukemia L1210 in mice.7  
 Tylophorine has anti-inflamatory properties.10 The molecular mechanism for the 
anti-inflamatory of phenanthroindolizidine alkaloids has been examined as an in vitro 
system.11 Tylophorine exhibited a potent suppression of nitric oxide production and did 
not show a significant cytotoxicity to the lipopolysaccharide interferons (LPS)/IFN-γ 
stimulated RAW264.7 cells. The RAW264.7 cell line is used in an assay of IFN-γ that 
measures the concentration of nitric oxide (determined by nitrite accumulation in the 
culture medium) generated by RAW264.7 cell line.11  
Tylophorine and its analogs such as DCB 3503 are commonly called tylophora 
alkaloids. These analogs have been targets of synthesis and modification for their 
significant cytotoxic activities.4 Tylophora alkaloids can be naturally extracted from its 
natural source only in small quantities; therefore,  DCB 3503 needed to be synthesized, 




 The Baker group has focused its efforts on the synthesis of DCB 3503 and 
analogues for evaluation as anti-cancer,3 anti-arthritic,11 and anti-lupus drugs.14 Work by 
Dr. S. Zhong, C. Kaczmarek15 and others have laid the foundation for this dissertation. 
Biological collaborators include Prof. Yung-Chi Cheng and his group at Yale University 
School of Medicine.  
19 
 












Scheme 1: The synthetic route to DCB 3503. 
 
 
















1.3.1 Synthesis of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (3) 
The synthesis of 3 was carried out by condensation of 3,4-
dimethoxybenzaldehyde and (3,4-dimethoxyphenyl)acetic acid in refluxing TEA and 
Ac2O in excellent yield. This condensation, also known as Perkin condensation,  yielded 
a mixture of both (E) and (Z) isomers in a ratio of (10:1),16 but isomer (E) was obtained 
exclusively by recrystallization.18 It has been noted that even without recrystallization, 
isomer (E) and (Z) can be used for the subsequent intramolecular oxidative coupling in 
order to obtain 5.17 
It has been reported that for product 3 the (E) isomer displayed a characteristic 
singlet resonance at 7.8 ppm for the vinylic β proton; the (Z) isomer for 3 displayed at 
approximately 7.1 ppm. This characteristic singlet for the (E) isomer has been found at 
7.8 ppm in the 1H NMR spectrum for product 3. It is important to indicate that a singlet 









This condensation was improved in the following steps: 
22 
 
1. In a 15 g scale, addition of 3,4-dimethoxybenzaldehyde and Ac2O were added 
until a solution was obtained. Then the TEA was added. At that moment, (3,4-
dimethoxyphenyl)acetic acid was added, and the mixture was slowly heated until 
it reached 100 °C (~1 h). 
2. Slowly H2O and a solution of K2CO3/H2O was added dropwise to the mixture (4–5 
h). 
3. The reaction was slowly quenched with 2 N HCl (2–3 h). 
If these steps were followed, the product would always precipitate as yellow 
powder in high yield. If these steps were not followed or the solutions were added 
faster, the formation of a sticky oily product would occur, which stopped the stirring bar, 






Scheme 2: Proposed mechanism for the formation of (E)-2,3-bis(3,4-
dimethoxyphenyl)acrylic acid (3). 
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1.3.2 Synthesis of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4)  
The esterification of 3 was achieved by addition of methanol under strongly acidic 
conditions. This reaction was improved to obtain high yields in the following steps: 
1. The starting material was dissolved in methanol and left stirring untilall 
components dissolved. 
2. The solution was heated slowly until 60 °C was reached. 
On the next day, the solution was left stirring until room temperature was 
reached. Then, solvent was removed by vacuum evaporation at not higher than 30 °C 
or the solution would turn into a purple oil. Under these conditions, the ester product 4 
precipitated into a yellow powder in high yield and was washed quickly with cold 
methanol. 
Product 4 (E) isomer displayed a characteristic singlet resonance at 7.8 ppm for 
the vinylic β proton. According to the literature, the (Z) isomer of 4 would be 
displayed at approximately. 7.1 ppm.18 This characteristic singlet for the (E) isomer has 
been found at 7.8 ppm in the 1H NMR spectrum for 4. It is important to indicate that 
singlet around 7.1 ppm was not found in the product (see Figure 3). 
 
Figure 3: Structure of compound 4 (E) and (Z) isomer. 
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1.3.3 Synthesis of methyl 2,3,6,7-tetramethoxyphenanthrene-9-
carboxylate (5): 
Product 5 was obtained by two methods: 
1.3.3.1 Method 1: VOF3 
 
 
Scheme 3: Synthetic conditions to obtain 5. 
 
Vanadium trifluoride oxide (VOF3) with trifluoroacetic acid (TFAA) was useful for 
the cyclization of phenanthrene rings that contained methoxy groups as substituents.2 It 
has been demonstrated by Halton and co-workers18 that from a survey of derivatives 
that oxygen functionality (-OMe groups) was necessary at the R4, R5 positions and/or 




Scheme 4: VOF3 reaction of compound 4 with R substituents 
Table 1: Partial table made by Halton and co-workers18 













 VOF3/TFA % yield VOF3/BF3
.
Et2O % yield 
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a OMe OMe H OMe OMe H 74 95% 
b OMe OMe H H H H 44 65 
c H H OMe OMe H H 61 82 
d H H H OMe OMe H 0 5 to 95 
n H H H H H H 0 0 
 
Halton and co-workers18 suggested the formation of a radical cation as a possible 
mechanism using VOF3/TFA. Vanadium trifluoride oxide is believed to affect the 
electron transfer and form radical cations with methoxy groups at the ortho position. It 
was experimentally demonstrated in Halton and co-workers18 and Jin and co-workers17 
that the two groups should be in the ortho position or the reactions failed. Vanadium 
trifluoride oxide acts as an oxidizing agent. This substance can gain electrons in a redox 
chemical reaction and becomes reduced in the process.  
This mechanism is believed to involve electron transfer and form radical cations 
on electron-rich substrates. Therefore, the aryl–aryl bond formation could occur by the 
coupling of a pair of radical cations in the presence of -OMe at the R1, R2, R4, and R5 
positions, followed by a radical attack on a un-ionized aryl group.  This hypothesis is 
also supported by Jin and co-workers.17 The cyclizations of phenanthere rings with -
OMe substituents at different position than R1, R2, R4, and R5 resulted in very low yield 
as reported by Halton and co-workers.18 This demonstrates the lower yield for product 




, chapter 2) compared to 5 (4 
–OMe in R1, R2, R4, and R5 positions), because it shows that two methoxy groups or 
oxygen functionalities are necessary in at least one of the aryl groups. These 
mechanisms are a possible explanation for products 5 and 15 using VOF3. This 
coupling occurred between these two aryl to give 5 which was evident for the newly 






Scheme 5: Proposed general mechanism for the formation of ring coupling. 
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1.3.3.2 Method 2: Anhydrous FeCl3  
Anhydrous iron(III) chloride has been used to synthesize the phenanthrene ring 
substituted with polymethoxy groups. This product is achieved via intramolecular 
oxidative coupling of E and Z 5 isomers using anhydrous FeCl3  in EtOAc. Vanadium 
trifluoride oxide (VOF3) can be used to form the phenanthrene ring as explained above; 
however, this reaction was improved to use in the scale-up process. Vanadium 
trifluoride oxide reagent has been limited due to toxicity, rigorous conditions, and price 
(Table 2). Therefore, the use of anhydrous FeCl3 was ideal for scale-up process. 
The conditions for the intramolecular oxidative coupling were simple. First, the 
starting material was dissolved in DCM below -10 °C. It was noticed that at room 
temperature the reaction was not completed, and a large amount of starting material 
(60%) was detected by TLC. Secondly, a fresh solution containing FeCl3 in EtOAc was 
added dropwise. The reaction was completed as soon as the addition of FeCl3/EtOAc 
was finished. The product was monitored by TLC that gave a characteristic bright blue 
color on anysaldehyde–H2SO4 spray.
19 It was also noticed that for scales higher than 
four grams the reaction was completed within 10 minutes. 
Table 2: VOF3 and FeCl3 reaction time, toxicity, and price. 
Reagent Reaction time (1g scale) Toxicity Price (Fisher) 
VOF3 4 h Corrosive $25 (5 g) 
FeCl3  10 min Low toxicity $22 (500 g) 
 
Anhydrous iron(III) chloride was added in large excess. Even though FeCl3 was 
completely dissolved in EtOAc, a large excess was needed to form the phenanthrene 
ring. Lowering the mol equivalents of FeCl3 has been attempted, but the presence of 
starting material was found. It is important to indicate that the FeCl3 must be anhydrous. 
The use of FeCl3·6H2O resulted in low yields, apparently due to the presence of water. 
The use of FeCl3·6H2O on silica gel was also investigated, but the reaction gave a lower 






Scheme 6: Proposed mechanism for the conversion of 4 (E) and (Z) isomers to 5. 
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1.3.4 Synthesis of (2,3,6,7-tetramethoxyphenylphenanthren-9-
yl)methanol (6): 
The reduction of 5 required one molecular equivalent of LiAlH4 to reduce the 
ester group to a primary alcohol. This simple reduction gave high yield and was 
quenched in by either of two methods: 
1. EtOAc and 2 N HCl. 
2. EtOAc and Na2SO4∙10H2O overnight 
 
The second method provided perfect conditions to obtain high yield, because 
Na2SO4∙10H2O is one of the ideal quenching reagents for sensitive compounds, and the 
granular form of LiOH that resulted facilitated filtration and isolation of product. 
 The reduction of the ester formed homotopic methylene hydrogens. The 1H NMR 
spectroscopy proved the complete reduction of the ester group to obtain the CH2 
hydrogens at 5.14 ppm, it was also noticed that the ester –Me peak at 4.01 ppm from 




1.3.5 Synthesis of (S)-methyl 5-oxo-1-((2,3,6,7)-
tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (7): 
This reaction required three steps: 
1. Halogenation: bromination of the alcohol was accomplished with PBr3 in chloroform at 
-10 °C. The reaction was carried it out in freshly distilled chloroform at cold 
temperatures, which was important in order to increase the final yield. Previously, 
chloroform was used directly from the bottle, and it gave a thick liquid as product, which 
gave unsatisfactory 1H and 13C NMR spectra and a low yield of the brominated product. 
Under these circumstances the crude product was used in the next step continued 
without any NMR characterization. However, after reading several papers with similar 
reactions, it was decided to distill the chloroform in order to remove any ethanol present 
(stabilizer) in the bottle. According to Fisher Scientific, chloroform only contains 0.75% 
of ethanol, but using this freshly distilled chloroform the brominated product gave a high 
yield and solid product that was easily characterized by NMR spectroscopy. Another 
important point to increase the yield was during quenching the reaction with ice. It was 
significantly important to let the ice melt completely and let the aqueous solution mix for 
at least 30 minutes before any organic extraction was attempted to significantly improve 
the quality of brominated product. If the organic extraction was separated in the 
presence of ice, the brominated compound did not turn solid even when distilled 
chloroform was used (see Scheme 7). 
 
 
Scheme 7: Procedure to transform OH to Br. 
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2. Coupling of L-glutamic ester HCl: The coupling of the brominated compound with L-
glutamic ester HCl was also significantly improved. In the past, this coupling was 
achieved by mixing the halogenated compound, the amino acid, and K2CO3 in DMF at 
the same time, and the reaction was run overnight at room temperature. The reaction 
was improved by mixing the brominated intermediate with the L-glutamic ester HCl 
completely and then adding K2CO3; the reaction was run from 65–70 °C overnight. This 
range of temperature was important, because it was found that any higher or lower heat 
will considerably lower the yield of the product. The ESI+ mass spectrometry for this 
intermediate was obtained and indicated complete coupling without any brominated 










3. Closing of the amino acid side chain: This final step was achieved by mixing the 
amino adduct in MeOH and AcOH. This reaction was improved as well. In the past, this 
reaction was accomplished by mixing MeOH and AcOH overnight at room temperature. 
The final product yield was improved by adding a 1:1 molar ratio of MeOH:AcOH and 
increasing the temperature up to 35 °C overnight. The temperature in this step was 





Scheme 9: Closing amino acid side chain. 
1.3.5.1 Important NMR observation for diastereotopic hydrogens on 
C11 for product 7. 
Geminal coupling 2J (H,H), bond angle, and effect of neighboring  electrons for 
diasterotopic hydrogens on C11. 
Bond angle 
Geminal coupling or 2J coupling is dependent upon the bond angle between the 
nuclei. Generally, the smaller the angle the bigger the coupling constant. The bond 
angle for the geminal hydrogens on C11 was 109.5°. This bond angle was calculated by 
drawing the structure in Tripos: Sybyl 8.0 molecular modeling program (molecular 
dynamics and MM4 minimization were used), as shown in Figure 4. She Figure 4 
indicates the dependence of the coupling constant on bond angle. 
 
 




Dependence of the magnitude of the geminal coupling constant on C11, J = 
14.60 Hz, and the HCH angle = 109.5° correlated with the expected values according to 
the graph above. 
Geminal coupling 2J (H,H) 
The diastereotopic hydrogens on C11 showed two distinct chemical shifts at 4.4 and 5.5 
ppm, 2J (H,H) = 14.60 Hz as shown in Figure 5  and 6. It was noted that these 
hygrogens were homotopic in starting material 6 before coupling to obtain product 7. 
The effect of neighboring  electrons. 
There are several major factors that affected the geminal coupling constant:20  
1. The hybridization of the atoms involved in the coupling. 
2. Bond angles and torsional angles. 
3. Bond length. 
4. The presence of neighboring -bonds. 
5. Effects of neighboring electron lone-pairs. 
6. Substituent effects. 
The diastereotopic hydrogens on C11 have different chemical shift primarily due 
to the neighboring -bonds and electron lone-pairs from the amide group. This effect 
was clearly present when the amide was formed in the intermediates, but the difference 
in chemical shifts was noticeably smaller when the amide was reduced to a tertiary 
amine by LiAlH4 to obtain compound 11. The new chemical shifts for the diasteretopic 





















































1.3.6 Synthesis of (S)-5-oxo-1-(2,3,6,7-tetramethoxyphenanthren-9-
yl)pyrrolidine-2-carboxylic acid (8): 
The hydrolysis of the ester 7 was accomplished under basic conditions of 2 N 
KOH followed by quenching by 2 N HCl. In the past, this reaction was quenched by 
H3PO4 until pH 3 at -10 °C. The product precipitated at low temperatures overnight, so it 
was left inside the freezer to maximize the yield of  product. This saponification method 
did give a good yield, and it would often form a great excess of white salts that mixed 
with the product 8 (white crystals). Thus, a mixture of product 8 and salts was 
unavoidable. In order to remove these salts, we had to add quickly cold water to 
dissolve the salts, but the water would dissolve the carboxylic acid product 8 as well. 
The addition of H3PO4 was stopped when pH 3 was reached, but lowering the pH 
to 1 did not help to avoid the formation of salts. It is important to indicate that any small 
presence of this salt for the next step would lower the cyclization reaction yield. 
Therefore, it was decided to add 2 N HCl until pH 1 was reached and extract the organic 
product with CHCl3, DCM, and Et2O.  In this way, no salts were formed and nothing 
precipitated. The carboxylic acid was extracted with CHCl3, DCM, and Et2O to obtain a 
yield of 95%. Product 8 was polar and soluble in water; thus it is essential to point out 
the necessity to extract the product with CHCl3 at least five times. The completed 
extraction was indicated by TLC (one spot seen at Rf = 0, since the carboxylic acid does 




1.3.7 Synthesis of (S)-2,3,6,7-tetramethoxy-13,13a 
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (9): 
 
Product 9 was obtained using two methods: 
1.3.7.1 Method 1: TFAA and BF3·Et2O  
The carboxylic acid 8 was converted to its mixed trifluoroacetic anhydride by the 
addition of trifluoroacetic anhydride in 1,2-dichloroethane or dichloromethane at room 
temperature. The compound was treated with the Lewis acid BF3·Et2O and queched 
with K2CO3, yielding the phenanthrene cyclized amido ketone 9.
21 This improved 
method was perfect for scale-up conditions, contrary to Method 2 that used SnCl4. 
These ketones exhibited a markedly characteristic yellow spot on TLC under 
ultraviolet absorption using anysaldehyde–H2SO4.
19 
This Friedel–Crafts cyclization had a higher yield when the solvent 1,2-
dichloroethane was used instead of dichloromethane. The choice of solvent was 
important to obtain higher yield and purity of the ketone. The final yield, after running a 
silica gel column, using 1,2-dichloroethane was around 70%; on the other hand, using 
dichloromethane the yield was 20–50%.  
A possible explanation for this lower yield could be the formation of 
rearrangements or by-products as expected by Bourry21,22 and Akué-Gédu.1 These by-
products were not detected by mass spectrometry for compound 9. Therefore, the 
reaction using BF3·Et2O as a Lewis acid apparently did not give a higher yield than 70%. 
The main concern was the formation of an alcohol chain by using 
dichloromethane as solvent at reflux. This by-product 9.1 could be formed that 
contained a CH2OH group in the α-position to the newly formed ketone function under 
reflux conditions.21 Therefore, in order to avoid this by-product, the Friedel–Crafts 
reaction using BF3·Et2O as Lewis acid must be run at room temperature. From 
experience, the expected ketone 9 was not formed when the reaction was heated to 
reflux overnight in an attempt to increase the yield. The formation of this by-product was 









Scheme 11: Proposed mechanism for formation of 9.1. 
A boron enolate 9A (Scheme 11) could be formed from the reaction of excess 
BF3·Et2O with the ketone 9 in the presence of trifluoroacetic acid (by-product after 
cyclization). Then, the remaining dichloromethane can be reacted with the enolate to 
give the chloromethyl ketone 9B. Therefore, dichloromethane was evaporated before 
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addition of K2CO3/H2O to avoid this by-product. The final step was the hydrolysis of the 
chloromethyl ketone using K2CO3/H2O to form 9.1, see Scheme 11. 
 
 





The characterization of product 9 was fully supported by 1D/2D NMR 
spectroscopy and MS. After cyclization, the H1 on C1 of each phenanthrene underwent 
a noticeable downfield shift due to the deshielding of the newly formed ketone. This 
effect was reversed after reduction with K-selectride for the formation of the secondary 
alcohol (see Table 3). This downfield shift was also reported in the publication by 
Buckley and Rapoport.2 
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H1 7.72  C1 108.14 
 
 





H1 7.59  C1 104.46 
 




The desired completion skeleton of DCB 3503 was accomplished under Friedel–
Crafts conditions using (COCl)2 to obtain an acid chloride to activate the carboxylic acid 
with SnCl4 as the Lewis acid. (see Scheme 16). This intramolecular Friedel–Crafts 
reaction consistenly gave a yield (60–70%) of product 9. 
Tin(IV)chloride is hygroscopic, toxic, and expensive; therefore, this reagent had 
to be replaced by an easier-to-handle, less toxic, and inexpensive Lewis acid in order to 
be applied for a scale-up process (see Table 4).  
In order to quench the excess of SnCl4, addition of 20 mL of water in 1 mL 
increments was useful before addition of 2 N HCl. Water quenched the SnCl4 slowly 
and gave a higher yield of a cleaner product. This mixture of water and 2 N HCl could 
not stay for more than 1 hour; otherwise, the compound 9 would decompose. 
   
Table 4: SnCl4 and BF3·Et2O reaction time, toxicity, and price 
 
Reagent Reaction time (1 gram scale) Yield % Toxicity 
Price 
(Fisher) 
SnCl4 6 h 70 toxic $37 (100 mL) 
BF3·Et2O 5 h 70 
Low 









Scheme 13: Proposed mechanism for the SnCl4-mediated synthesis of 9. 
 
Scheme 13, cont’d 
 
 
1.3.8 Synthesis of (13aS, 14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (11) 
 The final product was achieved by reduction of the amide group using 1 
molecular equivalent of LiAlH4. Unfortunately, this reaction did not give as high a yield 
as the previous reactions. This can be attributed to the sensitivity of the final compound 
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to harsh conditions such as the strong reducing agent. The final yield varied from 60–
80% depending on the quenching method. Two quenching methods were applied: 
1. Ethyl acetate and 2 N HCl for 30 minutes. 
2. Ethyl acetate and Na2SO4∙10H2O for 2 h or overnight. 
The best conditions were adding ethyl acetate at -10 °C and then stirring with 
Na2SO4∙10H2O for 3 h. Any other quenching method proved to lower the yield of 
product. 
In order to purify the crude product, column chromatography was used. The 
solvent system was 2:1:0.2 CHCl3:EtOAc:MeOH. Even though 11 was a highly polar 
compound, there was an unwanted side-product with m/z = 411.19 and [M+1]+ = 412.20 
that was detected using the DART mass spectrometer in positive-ion mode and by 
HPLC. The detection and separation of this side-product was difficult due to its similar 
polarity with that of 11, no coloration with anysaldehyde–H2SO4, and a close molecular 
weight to that of 11 (DCB 3503 = 409.19, [M+1]+ = 410.19). The only solvent method 
found to completely separate this side-product was 2:1:0.2 CHCl3:EtOAc:MeOH . 
An alternative synthetic route and biological analysis of this side-product is 
described in Chapter 3. 
1.3.8.1 Molecular modeling and dihedral angle between H14 and H13a: 
 Tripos: Sybyl 8.0 with MM4 was used to calculate the dihedral angle between 
H14 and H13a for product 11. This program was highly useful to determine the lowest 
energy conformation and predict the dihedral angle.  
The direct drawing using molecular modeling SYBYL 8.0:Tripos (minimization 
with MM4 and molecular dynamics). Figure 8. 
The predictions for dihedral angle and final energy can be seen in Table 5. 
 
Table 5: DCB 3503 dihedral angle molecular modeling results 
Structure Dihedral angle  Final steric energy 
(kcal/mol) 





















1.3.9 Attempted cyclization of 28 with (S)-2-
(methoxycarbonyl)pyrrolidinium chloride to obtain 29. 
 
A tentative pathway for the cyclization of 28 (Scheme 15) was 
unsuccessful. Similar Lewis acids, such as AlCl3
23, BF3·Et2O, SnCl4, and Sm(OTf)3, 
were tried to obtain the intramolecular cyclization, but these reagents were not suitable 
for the reaction. The coupling of the brominated intermediate 6.1 with the closed amino 
acid (S)-2-(methoxycarbonyl)pyrrolidinium chloride was highly successful giving 
excellent yield, see Scheme 18. The hydrolysis of 24 was a success giving 28 in high 
yields using 2 N KOH or NaOH.24 The next step was a failure, a different Lewis acids, 
molecular equivalents, variable temperatures, extended reaction times, different 
chlorination of carboxylic acids, and quenching methods failed to yield the ketone 29. 
Due to this failure of Friedel–Crafts cyclization, further efforts in this area were 
abandoned. Later on, it was found that Buckley and Rapoport2 also tried to these 
reagents with the free amido compound 28, and the results were unsuccessful as well. 
Chauncy attempted the cyclization of this free amide to also obtain negative 
results.7 Cycloalkylation of using AlCl3, BF3∙Et2O, Sm(OTf)3
25, SnCl4 (at reflux)
26 proved 
unsuccessful as well. According to his paper,7 he was successful to obtain the 
cyclization by using phosphoric acid at 90 °C with yields of 20–35%. These conditions 
were tried on 28, but it did not dissolve in phosphoric acid, even at high temperature 
around 200 °C. The procedure was abandoned. This reaction would have been highly 
useful because it would had eliminated two steps, and the necessity to reduce the 
amide, which gives a lower yield due to the sensitivity of the final compound 11 under 







A = CO2Cl2 SOCl2  CO2Cl2 TFAA  SOCl2  CO2Cl2 
B = SnCl4 AlCl3  Sm(OTf)3 BF3·Et2O SnCl4  AlCl3  
 
 







Chapter Two: Synthesis of DCB 3507 
2.1 Statement of Problem 
The objective was to effect the synthesis of an analog of DCB 3503 that lacked 
the MeO groups in the 6, 7 –position of the phenanthrene ring (see Figure 9). 
 The anticancer activities are to be examined to add to structure–activity 
relationship development among these compounds. 
 
 
Figure 9: Structure of DCB 3507. 
   DCB 3507: R1, R2 = H, R3 = OH 












The synthesis of DCB 3507 started in an undergraduate summer program 
sponsored by UT Science Alliance for two consecutive summers. This project was 
under the direct supervision of Dr. David C. Baker and Mr. Conrad Kaczmarek.  
The main objective to synthesize DCB 3507 was to find whether there was any 
difference in biological activity compared to DCB 3503, since it was a similar analog. In 
this way, it could give valuable information about structure–activity relationships and 
prove if four methoxy groups were absolutely necessary for biological activity against 
cancer cells.  
 A number of examples of Tylophorine analogues are known that lack 6, 7 
methoxy groups. One example is the antofine analogues. Their antitumor activity with 
different susbtituents on the phenanthrene ring has a variety of citotoxic activity against 
various cancer cells with lower potency than DCB 3503. However, no 6,7–desmethoxy 


















Scheme 15: The synthetic route to DCB 3507. 
 













2.3.1 Synthesis of (E)-3-(3,4-dimethoxyphenyl)-2-phenylacrylic acid  
(13) 
2.3.1.1 Condensation reaction to give C. 
The synthesis of C was first attempted in order to obtain a tylophorine analog 
with two methoxy groups in the phenanthrene ring moiety, as seen on Scheme 16. 
 
Scheme 16: Condensation reaction to obtain C 
This condensation reaction of C started with commercially available reagents. 
The synthesis required 3,4-dimethoxyphenylacetic acid (A, 30 g), benzaldehyde (B, 30 
g),  TEA (46 mL), and Ac2O (80 mL). This reaction was left running overnight at 100 °C. 
The detailed experimental observations can be found in the Appendix section. 
2.3.1.2 Condensation reaction to give 13. 
 
Scheme 17: Condensation reaction to obtain 13. 
The starting material was changed to synthesize DCB 3507 using two methoxy 
groups in positions 2 and 3 of the phenanthrene ring, as seen in Scheme 17. The 
starting commercial materials were 3,4-dimethoxybenzaldehyde (veratraldehyde 1), and 
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phenylacetic acid 12. The detailed experimental observations can be found in the 
Appendix section. 
 The product 13 was characterized and verified by using NMR and mass 
spectrometry. The theoretical exact m/z was 284.105, and the experimental m/z was 
found 285.111 using AccuTOF–DART in positive-ion mode. The key hydrogen 
resonance that verified the condensation reaction and stereochemistry product 13 was 
the characteristic singlet resonance ~7.8 ppm in the vinylic β hydrogen (Hβ) for the (E) 
isomer.  The undesired (Z) isomer would show Hβ ~7.1 ppm although the (Z) isomer 
was present in a ratio of 10:1, the (Z) isomer was not detected after recrystallization 
(See Figure 12).  
 
 
Figure 10: Compound 13 (E) and (Z) isomers. 
 
The Hβ in 13, which was originally the aldehydic H in the starting material 1, is 
more shielded in the (E) alkene (See mechanism in Scheme 19)  
It is known that hydrogen from aldehyde groups is shifted around 9.5–10 ppm, 
and alkene protons range from 4–5 ppm (without substituents), but this newly formed 
alkene Hβ was found at 7.891 ppm. This shift was expected due a large deshielding 
effect from to the benzene ring.  In Figure 11 the benzene and the alkene are coplanar, 
so the Hβ is further deshielded because of the additional deshielding effect from the 




Figure 11: Ring current effect in arenes and compound 13 in plane view. 
 
 The Hβ indicated the stereochemistry for the desired (E) isomer over the 
undesired (Z) isomer. The desired (E) isomer showed the predicted Hβ singlet at 7.891 
ppm, and the undesired singlet at 7.1 ppm was not found in the proton spectrum18 see 
Figure 12. 

























Scheme 18: Proposed mechanism for the formation of (E)-3-(3,4-
dimethoxyphenyl)-2-phenylacrylic acid (13) 
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2.3.2 Synthesis of methyl 2,3-dimethoxyphenanthrene-9-carboxylate 
(15) 
2.3.2.1 Method 1: VOF3 
 
 
Scheme 19: VOF3 reaction to obtain 15. 
 
  
 Vanadium(V) oxytrifluoride was used to form the phenanthrene system (Scheme 
19).2 This reaction was applied according to H. Pearson’s27 procedure. These reaction 
conditions were later successfully applied to DCB 3503, and a high yield of product was 
obtained. The newly formed phenanthrene ring showed a bright blue spot on TLC under 
anysaldehyde–H2SO4 stain. 
 This oxidative coupling reaction required at least 4.4 equivalents of VOF3 to close 
the ring.5 A low yield was obtained as an attempt to lower the amount of VOF3 needed. 
A mixture of starting material and product was seen on TLC and mass spectrometry. 
The separation of the product and starting material was difficult, because these two 
products had similar polarity; therefore, they could not be separated completely. 
 The use of VOF3 gave a high yield, but it had to be replaced by another reagent 
due to its high cost and limited amounts that were commercially available; therefore, 
VOF3 was not suitable to scale-up reactions. 
 2.3.2.2 Method 2: FeCl3/SiO2 
It has been proved that silica-bound ferric chloride (FeCl3/SiO2) can serve as an 
oxidant for aromatic coupling (Scheme 20).28 The results indicated that solid-supported 
FeCl3 could act as an electron-transfer oxidant
29 and it was environmentally better than 
VOF3.
16 This reaction provides an effective and less expensive (compared to VOF3) 





Scheme 20: FeCl3/SiO2 to obtain 15. 
 
The use of silica gel/FeCl3 as a solid-supported oxidant was the key to obtaining 
a higher yield in the intramolecular coupling reaction of 15. Anhydrous FeCl3 and 
FeCl3–SiO2 serve as Lewis acids for oxidative coupling reactions. The use of FeCl3 in 
EtOAc showed a very low yield (<15%) due to the lack of methoxy groups as explained 
for DCB 3503 in intermediate 5 by Halton and co-workers.{Brian Halton, 1984 #8} As an 
alternative reagent, VOF3 can be used to form the phenanthrene ring, but this reagent is 
expensive and toxic. Therefore, it could not be used for scale-up conditions (see Table 
6). 
 
Table 6: VOF3 and FeCl3/SiO2 reaction time, toxicity, and price  
 
Reagent Reaction time (1 gram scale) Toxicity Price (Fisher) 
VOF3 4 hours corrosive $25 (5 g) 
FeCl3/SiO2 48 hours 
Low 
toxicity $22 (500 g) 
 
The formation of 15 was verified and characterized by mass spectrometry and 
NMR spectroscopy. The exact molecular weight of 15 is 296.105, and ion was found at 
[M+1]+ = 297.106 using the AccuTOF DART in the positive-ion mode. The 
characterization by NMR spectroscopy was used (1H, 13C, and 2D NMR such as 
gHSQC and NOESY) to prove the structure. 
 The most important 1H NMR spectroscopy characterization of 15 was the 




Figure 13: Compound 15, phenanthrene ring in bold. 
 
The phenanthrene ring is a benzene derivative that is categorized as an aromatic 
compound; therefore, the chemical shifts spin–spin splitting,  J coupling for 15 gave the 
following expected results (see Table 7): 
Table 7: Chemical shift, splitting, and J coupling for 15 
Hydrogen Chemical shift (ppm) Splitting J coupling (Hz) 
H1 7.98 Singlet 0 
H4 8.44 Singlet 0 
H5 8.99 Doublet 8.39 
H6 7.62 Triplet 7.28 
H7 7.64 Triplet 7.30 
H8 7.25 Doublet 8.23 




NMR spectroscopic analysis: 
1. Chemical shifts: the seven aromatic protons showed the correct peaks in the 
aromatic region (6–9 ppm) due to the formation of the phenanthrene system. The 
chemical shift values for H1, H4, and H10 were expected to be less shielded due 
to the proximity of the methoxy groups in C2 and C3, and the ester group in C9. 
The rest of aromatic protons H6, H7, and H8 had to have similar shifts and be 
more shielded due to a similar environment with only hydrogens as neighbors.  
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2. Splitting: the splitting of H1, H4, and H10 had to be singlets, because they did not 
have any hydrogens as neighbors for spin coupling. The H5 and H8 showed the 
correct doublet as splitting for being only next to H6 and H7 respectively. The H6 
and H7, showed the expected triplet for having two hydrogen neighbors in H5, 
H7, and H6, H8 correspondingly. 
3. J coupling: The J coupling for H1, H4, and H10 were zero because they were 
singlets. The J coupling for H5, H6, H7, and H8 gave interesting results. It was 
expected very similar J coupling values for H5, H6, H7, and H8, but two different 
ortho coupling constants were found: 3J5,6 = 8.39 Hz and 
3J6,7 = 7.28 Hz, also 
3J8,7 = 8.23 Hz, and 
3J7,6 = 7.30 Hz, which can be seen in Figure 14 .  
 
Figure 14: Ortho coupling constants for (15). 
 The main reason for this J coupling difference is due to the different C–C bond 
lengths in the aromatic system.20 A similar example was found for naphthalene in 
Friebolin20, which is shown in Figure 15. 
 
 








Scheme 21: Proposed mechanism for the synthesis of 15 using VOF3 or FeCl3. 
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The mixture of SiO2 in FeCl3 was made fresh for the intramolecular coupling 
reaction. A certain amount of SiO2, preferably 1 equivalent, was left drying overnight at 
80 °C in the oven to avoid any moisture present in the silica gel. This dry SiO2 was 
poured into a mortar that contained 1 equivalent of FeCl3. These reagents were ground 
and mixed using a mortar and pestle. This mixture was poured immediately into a 
starting material solution of that in dichloromethane to be run for at least 48 hours at 
room temperature. 
The dryness of SiO2 was important for the experimental conditions. It was noticed 
that regular SiO2, without being dried in the oven overnight, gave low yields, and 
difficult-to-run columns were necessary to separate the product and starting material.  
The formation of the phenanthrene ring must be done prior formation of the 
alcohol by reduction. This reaction gave almost no product and a tacky solid if any 
hydroxyl group, including phenols was present in the starting material. See Scheme 22. 
 
 
Scheme 22: FeCl3 reaction in the presence of hydroxyl group. 
 
The possible side-product and mechanism was presented by Krishna et al.30 
There are possibilities that FeCl3 reacts as a Lewis acid and coordinates with the 
oxygen of the alcohol, facilitating nucleophilic attack of another alcohol on the electron-
deficient primary carbon, which is followed by deprotonation and regeneration of FeCl3. 
As a result, the FeCl3 reagent gives an ether instead of the expected aromatic 
phenanthrene ring (see Scheme 23).  
The formation of the ether could be the answer for the formation of the tacky 
product. This undesired product did not indicate the presence of any unreacted starting 







Scheme 23: Proposed mechanism for FeCl3 reagent in the presence of OH group. 
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2.3.3 Synthesis of (2,3-dimethoxyphenanthren-9-yl)methanol (16) 
 The reduction of 15 was accomplished by using one molecular equivalent of 
LiAlH4 to reduce the ester carbonyl to methylene hydrogens (see Scheme 24). 
 
 
Scheme 24: Reduction of compound 15. 
 
 These methylene hydrogens were homotopics and showed only one peak in the 
1H NMR spectrum. It was also noted that the ester peak at 4.05 ppm from compound 15 
was not present after the reduction. 
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2.3.4 Synthesis of (S)-methyl 1-((2,3-dimethoxyphenanthren-9-
yl)methyl)-5-oxopurrolidine-2-carboxylate (17) 
2.3.4.1 AB Spin system 
The synthesis of intermediate 17 required three steps from the alcohol 16. The 
same steps and conditions were repeated from intermediate 7 to synthesize 
intermediate 17. 
Intermediate 17 was characterized by 1H, 13C, gCOSY, gHSQC, and NOESY 
NMR spectroscopy. Some features of the 1H NMR spectrum are worth mentioning. The 
C11 protons in the tetracyclic base appeared as an AB spin system in NMR 
spectroscopy (see Figure 16). It is important to indicate that this effect was not seen in 
intermediate 7 due to the homotopic methylene protons. 
In the 1H NMR spectrum it can be seen that the four signals for the methylene 
protons on C11 in the region 5.5 to 4.4 ppm were not homotopic (equal intensities or 
one signal), because they had different magnetic shieldings. As a consequence, they 
gave separate signals. This feature is also known as “roof effect” or AB spin system. 
The inner lines were stronger than the outer lines. 
Analysis of the AB spin spectrum: 
It started by numbering the resonances frequencies of the four lines of the AB 
spectrum from left to right as f1, f2, f3, f4. As in the AX spectrum the coupling constants 
JAB is equal to the frequency interval between lines 1 and 2 or between 3 and 4: 
IJABI = If1 – f2I = If3 – f4I [Hz] 
IJABI = I5.577 – 5.529I = I4.486 – 4.437I = 14.55 Hz 
The chemical shifts are given by the centers of gravity of the line pairs 1, 2, 3, 
and 4. The chemical shifts difference can be determined by the following equation: 
 ∆v = √I(f1 – f4) – (f2 – f3)I   
√ (5.577 – 4.437) – (5.529 – 4.486) = 0.314 ppm = 0.311 * 300 = 94.48 Hz 
The roof effect is a typical indication of strongly coupled spin systems. In the 
case ∆v is zero, only a singlet appears in the spectrum. It means the AB system is 


























2.3.4.2 Geminal coupling 2J (H,H), bond angle, and effect of neighboring  
electrons for methylene protons on C11 of 17. 
Geminal coupling 2J (H,H) 
 The diastereotopic hydrogens on C11 (4.5 and 5.6 ppm) also showed a 
noticeable difference in chemical shifts, just like its analog intermediate 8. The geminal 
coupling constant was found to be 2J (H,H) = 14.55 Hz. 
Bond angle 
  
 The bond angle for the geminal hydrogens on C11 was also calculated drawing 
the intermediate using molecular modeling: Tripos: SYBYL 8.0 (dynamics, MM4 
minimization energy) as shown in Figure 17. The bond angle = 109.5°. It can be 
observed that 2J(H,H) = 14.55 Hz correlated with the predicted bond angle 109.5° in 
Figure 17. 
The major effect for the difference in the diastereotopic hydrogens in C11 was 
the presence of the amide group as explained for intermediate 8. This difference was 
smaller (2.9 and 3.2 ppm) when the amide was reduced to the tertiary amine with LiAlH4 






















2.3.5 Synthesis of (S)-2,3-dimethoxy-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H, 12H)-
dione (19) 
Compound 19 was obtained by two methods: 
2.3.5.1 Method 1 TFAA and BF3·Et2O 
The intermolecular Friedel–Crafts cyclization reaction of 18 using TFAA and 
BF3·Et2O was accomplished under the same conditions as used for 9 to obtain the 
ketone 19.21 
2.3.5.2 Method 2 (COCl)2 and SnCl4 
This cyclization was also obtained using (COCl)2 and SnCl4. Oxalyl chloride was 
added to prepare the carboxylic acid chloride, and tin tetrachloride was used as a strong 
Lewis acid to promote electrophilic addition to the aromatic system. This reaction 
required heating at 30 °C prior addition of SnCl4, but it was noticed that a higher yield 
was obtained when it was run at room temperature for at least four hours or overnight. 
In order to quench the reaction, addition of 2 N HCl was needed. This weak acidic 
solution must be added dropwise. It should be noted that water must be added before 2 
N HCl decompose the SnCl4. The characteristic yellow spot was also observed on TLC 
under ultraviolet light using anisaldehyde for both methods.  
Intermediate 18 was characterized by 1H, 13C, gCOSY, gHSQC, and NOESY 
NMR spectroscopy. The C9 protons appeared as an AB spin system. The NMR 
spectrum with the chemical shifts and the coupling constant are shown in Figure 19. It is 
important to indicate that this effect was also seen in intermediate 8. 
In the 1H NMR spectrum it can be seen that the four signals for C9 protons in the 
region 5.9 to 4.8 ppm did not have equal intensities. This feature is also known as “roof 
effect” or AB spin system. As in the AX spectrum the coupling constants JAB is equal to 
the frequency interval between lines 1 and 2 or between 3 and 4: 
IJABI = If1 – f2I = If3 – f4I [Hz] 









The aromatic H1 chemical shift of phenanthrene 18 undergoes a downfield shift 
due to the deshielding of the newly formed ketone 19. This effect was reversed after 
reduction of 19 with K-Selectride with the formation of the secondary alcohol 20 (see 
Table 8). 
 
Table 8: Comparison of 1H and 13C NMR shifts for compound 18, 19, and 20 
 
 





H1 6.93  C1 119 
 
 





H1 9.03  C1 125.1 
 
 









Product 19 was always produced in lower yield than 9. The percent yield ranged 
from 50–60%. Several conditions were changed, such as temperature, molecular 
equivalents of TFAA, mol equivalent of BF3·Et2O, reaction time, and quenching time to 
improve the yield, but the cyclization could not be improved. 
A possible explanation for this lower yield can be explained by Akué-Gédu and 
co-workers.1 They postulated that the presence of deactivating functional groups in the 
aromatic moiety decreased the rate of ketone formation. On the other hand, cyclization 
of acids with electron-rich aromatic moieties gave better yields. Akué-Gédu et al gave 
the following examples, Scheme 25.1 
 
Scheme 25: Akué-Gédu’s reaction example   
 
Thus, the presence of electron-rich methoxy groups in the phenanthrene ring 
activated the aromatic moiety to form the Friedel–Crafts cyclization of 18. In the reaction 
mechanism, shown in Scheme 26, it can be observed that after the cyclization produced 
by the  aromatic bond on C9–C10, it formed a carbocation on C9. This positive charge 
can be delocalized in the phenanthrene due to the aromatic  bonds. This delocalization 
can be enhanced by the presence of electron-donating groups, in this case methoxy 
groups (OMe), which donate their lone-pair of electrons localized on the oxygen. These 
pair of electrons created a resonance to delocalize the positive charge. It is worth 
mentioning, that the presence of only two methoxy groups vs. four methoxy groups 
appears to have lowered the yield. The two methoxy groups 9 gave a lower yield than 
the four methoxy groups 19; meanwhile, according to the literature, the total absence of 
electron-donating groups (only hydrogens) or the presence of electron withdrawing 
groups on the phenanthrene ring produced almost zero percent yield. Such behavior is 








Scheme 26: Reaction mechanism for the synthesis of 19. 
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2.3.6 Synthesis of (13aS, 14S)-14-hydroxy-2,3-dimethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (20)  
Stereocontrolled ketone reduction of the intermediate 19 on C14 to the 
secondary alcohol 20 with (S) stereochemistry was achieved by either K-selectride or L-
selectride in high yield. The decision to synthesize the secondary alcohol with the (14S) 
stereochemistry was mandated given the higher biological activity of (14S) DCB 3503 in 
contrast to (14R) DCB 3501 (see Scheme 27). 
 
Scheme 27: DCB 3503, 3501, and undesired product 
The two diastereotopic protons on C9 have noticeably different chemical shifts. 
This difference is around 1 ppm (4.5 and 5.4 ppm). This chemical shift difference could 
be due to the oxygen’s lone pairs of the amide group that deshielded the hydrogen on 
the same face of the nitrogen, which is more downfield; meanwhile, the other hydrogen 
is more upfield because it is more shielded as shown in Figure 20.   
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Figure 20: C9 diasteromeric protons of compound 20. 
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2.3.7 Synthesis of (13aS, 14S)-2,3-dimethoxy-9,11,12,13a,14-
hexahydrodibenzo[f,g]pyrrolo[1,2-b]isoquinolin-14-ol (21) 
 
The reduction of the amide or lactam intermediate 20 to a tertiary amine 21 was 
achieved by 1 equivalent of LiAlH4 with high yield. This reduction was quenched by 
EtOAc and two options: 2 N HCl or Na2SO4∙10H2O. It was noted that using the second 
reagent gave a little higher yield because the final product is more stable under neutral 
conditions, instead of acidic or basic conditions. Unfortunately, this product was 
unstable and tended to decompose when exposed to light, air, and solvent. 
Final product 20 was characterized by 1H, 13C, gCOSY, gHSQC, and NOESY 
NMR spectroscopy. The C9 protons did not appear as an AB NMR spin system like the 
previous intermediates. The C9 proton chemical shifts moved upfield due to the 
reduction of the amide, from 4.5 to 5.4 ppm and from 2.9 to 3.2 ppm. It is clear that the 
deshielding effect of the amide kept the C9 protons at downfield. This difference 
became really shorter when the lactam was reduced with LiAlH4 to obtain the final 
product 21 as shown in Figure 21. The effect of neighboring -electrons from the amide 


































2.3.8 Karplus equation and molecular modeling applied to DCB 3507 
DCB 3507 has a secondary alcohol on C14 with a stereochemistry (S) due to a 
previous stereoselective reduction using K-Selectride. In order to confirm this 
configuration, some analysis was done to confirm this chiral carbon that included 
dihedral angle, 3J coupling constant, Karplus equation, and molecular modeling 
(Tripos:SYBYL 8.0). 
2.3.8.1 Dihedral angle analysis 
DCB 3507 has a dihedral angle between hydrogens on H14 and H13a as shown 
in Figure 22. 
 
Figure 22: Dihedral angle case A and case B 
The chirality is defined as 13aS by synthesis from the precursor amino acid 17. 
There was no evidence of racemization during synthesis which would have produced a 
diastereomeric mixture that would have been seen in the NMR spectrum. The dihedral 
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angle  for DCB 3507 (CASE A) should be small if hydrogens on C14 and C13a have 
chiral carbons (13aS,14S); in order words, both hydrogens are “up” as shown in Figure 
20 , probably less than 60°. If the stereochemistry on C14 and C13a would have a 
configuration (13aR,14S) (CzASE B); then, the dihedral angle should be much larger 
than 60°. The dihedral angle could be properly measured by a combination of several 
methods, such as vicinal coupling constant 1H NMR (3J, H–C–C–H), the Karplus 
equation, and molecular modeling. 
2.3.8.2 Vicinal coupling constant analysis 
The 3J coupling constant between the vicinal protons H14C and CH13a was 
measured from 1H NMR spectroscopy at 300 MHz. The hydrogen on C14 appeared at 
4.75 ppm as a doublet with a coupling constant J = 1.78 Hz, as shown in Figure 24. The 
coupling constant for C13a could not be measured because it was highly overlapped by 
other methylene hydrogens.  
2.3.8.3 Karplus equation analysis 
Vicinal coupling or 3J coupling is dependent upon the dihedral angle between the 
nuclei. The magnitude of these couplings is generally the smallest when the torsion 
angle is close to 90°, and largest (around J = 12 Hz) at angles of 0 and 180°. The 
relationship between dihedral angle and coupling constant is known as the Karplus 
relationship,20 and the following Figure 23 depicts a typical Karplus curve. For a 
small, relatively rigid molecule, where a small coupling constant (1.78 Hz) is observed, 
the small gauche angle as in Case A (Figure 22) is supported. This together with the 


























The coupling constant J = 1.78 Hz was inserted into the Karplus equation, and it 
gave a theoretical dihedral angle = 60.5°.  
2.3.8.4 Molecular modeling (Tripos:Sybyl 8.0) 
The application of molecular modeling using the program Tripos: SYBYL 8.0 
(dynamic and MM4 minimization) was used to calculate the dihedral angles.  
The drawing of the structure and use of molecular dynamics and MM4 to 
minimize energy was the best approach. See Figure 25. 
Table 9 resumes the predicted calculations from molecular modeling for DCB 3507. 
Table 9: DC 3507 dihedral angle molecular modeling results 
Structure Dihedral angle (Ǻ)  Final steric energy (kcal/mol) 
DCB 3507 from drawing 52.2 11.3392 
 
A similar analysis to calculate dihedral angles was applied to DCB 3503 in 
Chapter 1. Moreover, two additional structures were built using molecular modeling for 
DCB 3507 with dihedral angles higher than 60° by increasing theoretical dynamics and 
MM4 in SYBYL. These structures can be seen in Figures 23 and 26. Table 10 includes 
data from DCB 3503, DCB 3507 and the two additional structures which were arranged 
according to steric energy (from low to high). 
 
Table 10: DCB 3507 and DCB 3503 dihedral angle molecular modeling results 
 





1.DCB 3507  52.2 11.3392 25 
2.DCB 3503  51.1 12.5425 8 
5.DCB3507  69 25.408 26 
 
 
 The above table 10 gave us an important conclusion for the dihedral angle 
approximation for either DCB 3503 or DCB 3507. It can be concluded that the dihedral 
angle should be more than at 50.4° and less than 60°, because at 50° the steric energy 
is almost double that 52.2°, and the dihedral angle should be no higher than 60°, 
because the steric energy increases and the molecule starts to bend in the pyrrolidine 





















Figure 25: Direct drawing and minimization molecular  





















Chapter Three: Synthesis of DCB 3508 
3.1. Statement of Problem 
The synthesis of DCB 3508 was carried out to compare its activity with that of  
DCB 3503 and DCB 3507. DCB 3508 is an analog of DCB 3503 in which the compound 









The idea of synthesizing DCB 3508 (Figure 27) came as a result of an 
unexpected impurity found in the mass of DCB 3503 and an interest to find the 
biological activity for an open-ring analog to DCB 3503.  Compound 11 (DCB 3503) 
had an exact mass of 409.19. When it was run using DART in positive-ion mode, it 
showed the expected fragment [M+1]+ 410.197, but it also showed a peak at 412.213. It 
came to my attention that it might be a side-product with higher polarity than 11, 
because the development of TLC (2:0.5 CHCl3:CH3OH) showed an almost colorless 
spot at the baseline of the TLC when it was stained with anysaldehyde–H2SO4. Also, 
when running the impure 11 on HPLC, it showed a small peak that was very close to 















3.3.1 Synthesis of (S)-methyl-1-(2,3,6,7-tetramethoxyphenanthren-9-yl) 
methyl)pyrrolidine-2-carboxylate (24) 
 
The idea of coupling (S)-2-(methoxycarbonyl)pyrrolidinium chloride 23 directly to 
6.1 to obtain 24 has been tried before without success using K2CO3 in DMF but 
according to Fülep and co-workers,24 it could be accomplished using K2CO3 in acetone 
with NaI at room temperature, and for my reaction it gave a 40-50% yield. A similar 
alkylation was reported by Akué-Gédu1, and Vanecko and West32 suggested an 
increase in temperature. This N-alkylation was a complete success only after heating 
the solution at reflux for 48 hours; the product was produced in high yield and almost no 
by-products were found. 
It was interesting to indicate that Govindachari and co-workers33 tried a similar 
alkylation without success under Marchini and Belleau’s conditions. Govindachari used 
2,3,6,7-tetramethoxy-9-chloromethylphenanthrene with proline ester, dissolved them in 
dry toluene, and refluxed with stirring for 20 h. However, he was successful in obtaining 
the alkylation under the same conditions using prolinol, instead of proline ester. 
Therefore, the following are conclusions. 
1. The presence of Br or I as a leaving group in the starting material 6.1 determinated 
the successful reaction. It seemed that this alkylation could not be completed if Cl was 
the as leaving group.  
2. According to Govindachari et al,33 the alkylation of 2,3,6,7-tetramethoxy-9-
chloromethylphenanthrene and proline ester undergoes a self-condensation of proline 
ester much faster than reaction with the halide. This could have been avoided using a 
better leaving group (Br or I) 
3. The choice of solvent is important for the alkylation. Although DMF is a well-known 
solvent for alkylations, it did not work for this case; however, acetone and dry toluene 
was found to be useful. 
4. The strength of the base had an important role for this alkylation. Potassium 
carbonate is a weak base that is used for easy alkylations (good leaving groups and 
strong nucleophiles). The use of strong bases, such as NaH, was not used to avoid self 
alkylation of proline or elimination reaction of the halides.  
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 The structure of 24 was confirmed and characterized by mass spectrometry and 
NMR spectroscopy. The exact molecular weight of 24 was 439.199, and it was found as 
m/z 440.205 by AccuTOF-DART in the positive-ion mode. NMR spectroscopy supported 
the structure. The most important prove of that the coupling reaction between 6.1 and 
proline ester 23 was successful was the formation of the diastereotopic geminal 
hydrogens (4.48, 3.53 ppm) at C1 for 24. It is also important to indicate that the starting 
material 6.1 did not have diastereotopic hydrogens on C1; they were homotopic protons 
giving one signal (4.99 ppm) (see Figure 28).  
These geminal diasterotopic protons in 23 were also proved by 2D NMR 
spectroscopy. The gCOSY spectrum showed a strong correlation between 4.48 and 
3.53 ppm, which could indicate either geminal or vicinal hydrogens. The gHSQC 
spetrum confirmed that they were geminal hydrogens, because these two hydrogens 
(4.48, 3.53 ppm) were on the same F2 axis that correlated to only one carbon. The 
NOESY spectrum also indicated a strong proximity through space. 
 The diastereotopic hydrogens on C1 in product 23 were also proved by J 
coupling measurements. The diasterotopic hydrogens on C1 showed two distinct 
chemicals shifts, but the same geminal coupling 2J (H,H) = 12.13 Hz  (see Figure 29 
and 30).   
 
 












Figure 30: J coupling of compound 24 at 4.48 ppm. 
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3.3.2 Synthesis of (S)-1(-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methylpyrrolidin-2-yl)methanol (25) 
 
DCB 3508 was synthesized in two easy ways. Both pathways require reduction 
(see Scheme 29). 
First pathway: Product 25 was accomplished by reduction of 7 with 2 equivalents of 
LiAlH4 to reduce both the ester and lactam. This product 25 was obtained in high yield 
without any side products. 
Second pathway: Product 25 was accomplished by using 1 equivalent of LiAlH4 with 24 
to obtain 25. This reaction also gave a high yield of product, and TLC showed the 
same Rf = 0.06 value as the impurity seen on the impure DCB 3503. 
 
First reaction pathway: 
 
 
Second reaction pathway: 
 






The structure of the impurity 25 was found using TLC, HPLC, MS, and NMR 
spectroscopy. The total mass of the uncharged impurity had to be [M]: 411.20. The TLC 
showed a spot almost on the TLC baseline that indicated a higher polarity than that for 
11 (Rf = 0.13) (see Figure 31). Using this information, several possible 
structures were formulated that contained a [M] of 411.20 and had higher polarity than 
11. The structure of 25 was the best candidate due to the perfect mass match and the 
free alcohol that increased the polarity. The use of 1D and 2D NMR spectroscopy 
(gCOSY, gHSQC, and NOESY) proved the structure.  
The possibility to obtain chemically 25 as a by-product from the reduction of 11 
using LiAlH4 could not be reasonable. It was possible that unreacted compound 8 was 
carried along with the product during the last two steps of the synthetic path, finally 
being reduced with LiAlH4. It is important to indicate that compound 8 was observed on 
TLC in very small quantities at Rf = 0. HPLC was then used to find any possible by-
product that might not be seen on TLC. The possible reaction route for this by-product is 









Scheme 30: Reaction route for by-product 25. 
 
Compound 25 was synthesized in order to be assayed in the 60-cell 
screen for antitumor activity at the National Cancer Institute. This compound was an 
analog of DCB 3503 with potential anti-cancer properties. Unfortunately, this compound 
25 was not as potent as DCB 3503.  
Similar polar phenanthrene-based tylophorine derivatives containing a prolinol 
were synthesized and evaluated as potential antitumor agent by Wei and co-
workers.34(Figure 32). These structures (B and D) are shown below. 
These compounds were evaluated for cytotoxic activity against the A549 human 
cell cancer line as described in the paper by Wei and co-workers. 34 It is important to 
indicate that compound A and D showed the highest potency with IC50 values of 0.27 
and 0.16 μM, respectively, which are currently used as anticancer drugs. 
These compounds contained structural similarities to DCB 3508.  A core 
phenanthrene structure with an open chain at C10, a hydroxyl terminal group in the 
pyrrolidine structure, a methoxy group on C6, and 1,3-dioxolane moiety groups 









Table 11: Partial table from the paper of Wei et al29 








Chapter Four: Synthesis of DCB 3509 
4.1 Statement of Problem 
We obtained the biological results from DCB 3503, 3507, and 3508 conducted at 
the NCI. These data were plotted in the molecular modeling program, CoMFA, to predict 
biological activity for a range of analogs. CoMFA predicted  high biological activity for 

































Synthesis of DCB 3509 came from an interest to explore the biological activity of 
a DCB 3503 analogs with a short aliphatic chain with a hydroxyl group at the end on the 
aromatic C3 position. DCB 3509 will be submitted soon for biological analysis at the 
National Cancer Institute. Meanwhile, CoMFA, a molecular modeling program, predicted 




















































Scheme 31: The synthetic route to DCB 3509. 
 
 







































The total synthesis of DCB 3506 or 36, as described in Scheme 34, has been 
previously accomplished by Mr. Conrad Kaczmarek in the laboratory of Dr. David Baker 
in 2004. The discussion of DCB 3506 can be found in his MS Thesis. Therefore, since it 
was not an original work by this author, I did not include any chemical discussion in this 
dissertation. However, the synthesis of 36 is covered in the experimental section in this 
dissertation. 




The synthesis of 37 was accomplished by an alkylation of 36 by 3-
bromopropanol using K2CO3 as base. The alkylation was run at 70 °C for 48 hours, 
because after only 24 hours the alkylation was incomplete, and some starting material 
was detected by mass spectroscopy. If this was the case, 0.5 molecular equivalents of 
3-bromopropanol linker arm and K2CO3 was added which reflux overnight to complete 
the reaction, which solved the problem. 
This alkylation gave an exclusive substitution at the phenolic oxygen on C3 as 
shown in Scheme 32. Because the phenol is a stronger acid than the secondary OH on 
C14 a mild base (K2CO3) was used to achieve stereoselectivity; therefore, strong bases 
such as NaH and hydroxides of alkali metals and alkaline earth metals like NaOH and 
Ca(OH)2 were avoided.  
 
 





The exclusive substitution on the phenol instead of the secondary alcohol was 
proved by mass spectrometry and NMR spectroscopy (Figure 34). 
 
Figure 34: Possible substitutions for compound 37. 
 
Mass spectrometry (AccuTOF-DART in the positive-ion mode) of 37 indicated an 
exact mass of [M+1]+ = 454.215 and molecular fragment [M-OH]+ = 436.211 that 
corresponded to the ionization of the secondary alcohol. In the event that the secondary 
alcohol was alkylated by the 3-bromopropanol, the exact mass would be 453.215, that 
is the same as 37, but it would leave a free phenol that is easier to fragment due to the 
aromatic ring, and be detected than a primary alcohol; therefore, its expected fragment 
[M-OH]+ =  437.220, was not found. The molecular ion of the fragmented phenol was 
stabilized by the ring, thus increasing the probability of its appearance than a primary 
alcohol.35 This ion fragment 437.220 was not detected by mass spectrometry; therefore, 
there is a high probability that alkylation went exclusively to the phenol. 
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There was another product that could be produced. A potential quaternary amine 
could be formed if the tertiary amine alkylated the 3-bromopropanol, as shown in 
Scheme 36. 
 
Scheme 33: Alkylation of 36 at the tertiary amine. 
The possibility of forming a quaternary amine over alkylation in the phenol is low. 
This cationic compound would be unstable and undetectable by mass spectrometry, 
because DART–ESI in positive/negative mode does not detect cationic/anionic 
compounds. In order to easily rule out possible this side-product, we turned to NMR 
spectroscopy. The 1H NMR spectrum clearly showed the methylene triplet at 4.22 ppm 
with an integration of 2H that corresponded to C1 on 37 (Figure 35). The downfield 
chemical shift of C1 at 4.22 ppm was predicted due to the deshielding effect of the 
oxygen’s lone pair electrons. On the other hand, if the formation of a quaternary amine 
would exist, it would give a methylene multiplet for C1 with an expected chemical shift at 
3.22 ppm with an integration of 2. This chemical shift or multiplet was not seen in the 1H 








Figure 36: Molecular modeling structure for compound 37. 
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Chapter Five: Synthesis of Biotinylated Tylophorine Analog 
 
5.1 Statement of Problem 
 Another project was the synthesis of a tylophorine attached to an aliphatic chain 
of 6 carbons with a biotin 41, to help identify the protein receptor(s) in the cancer cell. 
Biotin is a naturally occurring compound that binds with high affinity and specifity to 
avidin and streptavin proteins.  The bond formation between biotin and avidin is rapid 
and unaffected by most extremes of pH, organic solvents, and denaturaturing agents. 
These conditions are ideal for the construction of a robust biological probe. 
We were aware of the strength and specificity of the avidin–biotin complex; 
therefore, these biotin and linker arms are the best tools that will help us to understand 
the reaction mechanism of our tylophorine (DCB-3503) in the cell. This biological 
research will be done by our collaborator, Dr. Y.-C. Cheng at Yale University School of 
Medicine. 
One of the main problems would be the attachment of biotin through a peptide 
bond. The attachment was considered through different intermediates in the synthetic 
route. 
Another important problem would be the nucleophile at the end of the aliphatic 










The biotinylation of DCB 3503 via a tether was made to do studies of the 
molecular mechanism of DCB 3503 in cancer cells at the laboratory of Dr. Y. C. Cheng 
at Yale University.  
The remarkably high affinity (Kd = 10
-5 M-1) of the vitamin biotin for the 
glycoprotein avidin has been used as a powerful tool in a wide variety of bioanalytical 
applications. In the past, researches have routinely employed a six-atom (amino 
caprolyl) linker chain between the biotin and active compounds in vatious chemical 
application with great success. Following this idea, our lab decided to link our DCB 3503 
with a tether, in this case a saturated chain of 6 carbons to biotin.  
The author decided to attach a linker not higher than 6 carbons, because of 
possible lipophilicity problems inside the cell. Also a linker with less than 4 carbons has 
been reported as unsuccessful on experiments. Therefore, a 6 carbon member link was 
considered ideal.  
This synthesis turned out to be challenging due to the functional groups in DCB 
3506 and tendency of DCB 3506 to undergo further reactions. Several synthetic routes 
have been tried; two routes reached the final step to obtain the final compound, but 
unfortunately failed in the last step. 
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Scheme 34: The synthetic route to synthesis of biotynilated tylophirine analog. 
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The synthesis of 38 was achieved under the same conditions as those for 37. 
The alkylation required a commercially available 1,6-dibromohexane to be used as 
linker arm, the intermediate 35 tylophorine analog, and K2CO3 as a weak base. 
This reaction was run at 75 °C for 48 hours. It was also noticed that for only 24 
hours the reaction was incomplete, because mass spectrometry indicated presence of 
starting material. In order to solve this problem, 0.5 equivalents of 1,6-dibromohexane 
and K2CO3 were added to the solution with reflux overnight. At room temperature, the 
solvent was vacuum evaporated at 35 °C until it turned into a mixed solid/liquid phase. 
Then 1:2:1 EtOAc:hexanes:Et2O was added , and the solution was left stirring for 30 
minutes at room temperature, and product 38 precipitated as yellow powder in high 
yield. 
 The presence of the terminal Br gave the characteristic mass peaks for halogen 
compounds. It is known, that a compound that contain one bromine atom would have an 
M+2 peak almost equal in intensity to the molecular ion because of the presence of a 
molecular ion containing the two isotopes 79Br and 81Br in an approximately ratio 1:1 
(50.5:49.5). This means that a compound containing 1 bromine atom will have two 
peaks in the molecular ion region as shown in Figure 38. 
 
Figure 38: Characteristic peak intensities for a monobrominated compound 
 In compound 38, the exact molecular mass was [M] = 571.157. The protonated 
(including a hydrogen) ion 38 [M+1]+ = 572.167 and [M+2]+ = 574.167 with almost two 
high-intensity peaks were found in the mass spectrum. The ion fragment [M-OH]+ = 
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554.171, for which the theoretical exact mass is [M-OH]+ = 554.154 was also present. 
Therefore, mass spectrometry of 38 proved the presence of the alkylated compound. 
(See Figure 40). 
 The NMR characterization of 38 also corresponded to the predicted chemical 
shifts. The most important peak found in this structure was the aliphatic methylene 
hydrogens on C1, see Figure 36, because these two hydrogens would have an unique 
chemical shift around 4.24 ppm due to the presence of oxygen, a triplet multiplicity, and 
an integration of 2H. On the other hand, the methylene hydrogens on C6 had a 
chemical shift around 3.50 ppm as expected due to the presence of bromine. 
 There are two other possibilities for alkylation, but these were discarded. The first 
possibility would be the alkylation of the secondary alcohol, but primary alcohols are 
weak nucleophiles and could not compete with phenol anion which is a stronger 
nucleophile. The second possibility would be the alkylation of the nitrogen in the amide 










Figure 40: Mass spectrum of compound 38 
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5.3.2 Synthesis of (13aS,14S)-3-(6-azidohexyloxy)-14-hydroxy-2.6.7-
trimethoxy-12,13,13a,14-tetrahydrobibenzo[f,h]pyrrolo[1,2-
b]isoquinolin-11(9H)-one (39)  
 
The synthesis of product 39 was achieved by a displacement of the bromo group 
of 38 by an azido group. This simple transformation was a successful reaction that gave 
39 in high yield and as a stable product. 
The exact molecular weight of 39 was proved by AccuTOF–DART position-ion 
mode mass spectrometry. The exact mass was [M] = 534.248, and its experimental 
mass was found [M+1]+ = 535.253, with an ion fragment [M-OH]+ = 517.237, for which 
the theoretical fragment mass is [M-OH]+ = 517.245. Neither the starting material 38 nor 
its ion fragments were present in the mass spectrum. The mass spectrum is shown in 
Figure 42. 
The TLC plate of 39 had a smaller Rf than 38. This smaller Rf was expected, 
since the brominated 38 is a little less polar than the azide 39 as seen on Figure 41. 
 
Figure 41: Rf values for compound 38 and 39. 
 
 The complete characterization was done by NMR spectroscopy. The product 39 
was proved by using 1D, 2D (gCOSY, gHSQC, and NOESY). All the correlations and 
chemical shifts were found in the expected chemical shifts. 
 It was noticed that product 39 was highly stable under light, heat (40–50 °C), 
solvents, and air. It was easy to be detected under UV light and could be purified by 
silica gel column chromatography, with the solvent system 2:1:0.5 CHCl3:EtOAc:MeOH. 
The solvent system needed EtOAc to slow the column to separate any small traces of 






Figure 42: Mass spectrum of compound 39.
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5.3.3 Synthesis of (13aS,14S)-3-(6-aminohexyloxy)-2,6,7-trimethoxy-
9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-
ol (40)  
 
The synthesis of 40 was performed by reduction of the azide and lactam group 
from the intermediate 39 with 2 equivalents of LiAlH4. The double reduction reaction 
transformed the azide into a primary amine and reduced the cyclic amide group or 
lactam into a tertiary amine. In order to verify the product 40, the following tests were 
done: 
1. Ninhydrin stain test: This functional group-selective ninhydrin was used to 
detect the presence of a primary amine on TLC chromatography, which showed a 
positive result with a big and strong purple-blue spot that stained almost immediately at 
the bottom of the TLC plate (after heating with a heat gun). A separate TLC plate was 
stained with anysaldehyde–H2SO4 to detect any presence of starting material 39. No 
starting material or side-product was found on TLC. Primary aliphatic amines bind 
strongly to silica gel, so primary amines would not be expected to migrate on silica gel 
TLC; therefore, the primary amine compound stayed at the bottom. This test also 
showed positive, because the purple stain spot was at the base of the silica gel plate. A 
representative picture of TLC plate of starting material 39 with Rf = 0.25 on 
anisaldehyde, and product 40 with Rf = 0 on ninhydrin is shown in Figure 43. 
 
 
Figure 43: Rf values for 39 and 40. 
 
 
2. Mass spectrometry: The molecular weight was determinated using 
AccuTOF–DART in the positive-ion mode. The exact mass of 40 with addition of H+ was 
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[M+1]+ = 494.278. This protonated product and ion fragment [M-OH]+ = 477.275 were 
detected as high-intensity peaks on mass spectrometry, as shown in Figure 45. 
The following Table 12 shows the theoretical mass calculation and experimental 
mass detected on AccuTOF DART positive-ion mode for the [M+1]+ and [M-OH]+.  
 
Table 12: Compound 40 theoretical and experimental mass 
Product/fragment Theoretical mass Experimental mass 
[M+1]+ 495.278 495.279 
[M-OH]+ 477.275 477.271 
 
The following structures, Figure 44, represent 40 as product [M], and its ion 
fragment [M-OH]+ found on mass spectroscopy. 
 
 
Figure 44: Molecular weight and fragment ion for compound 40. 
 
It is important to indicate that no starting material 39 [M+1]+ = 535.248 or its ion 










3. HPLC: The HPLC showed a fairly clean crude product with a major peak with 
high intensity that represented the product. 
Unfortunately, this product was highly sensitive to heat and unstable. It was 
noticed that during vacuum evaporation the product decomposed at 35 °C, turning from 
a yellowish solution to a brownish oily product. Therefore, the solvent had to be removed 
using vacuum evaporation at room temperature. This product seemed to decompose 
after few hours of being made. It is known by experience that after overnight in the 
vacuum pump the product would not show the same high intensity peaks on the Accutof-
DART positive-ion mode, and the intensity of the ninhydrin spot did not have the same 
strong purple stain. Under these circumstances, this amine had to be directly used for 
the next reaction without any purification. 
Changing the conditions for the reduction reaction were tried in order to improve 
the yield and quality of product.  
1. The molecular equivalents of LiAlH4 were reduced, since the reduction 
required only two molecular equivalents of LiAlH4 to reduce the azide and lactam group, 
only 25% of the LiAlH4 was taken out to reduce the azide and lactam group, but the 
reaction still showed presence of starting material. 
2.  The duration of the reaction was reduced from overnight to six and three 
hours respectively, in different reactions, but the same sensitive product always resulted.  
Then, three different quenching methods were used to improve the stability of the 
product: 
1. EtOAc and 2 N HCl: Ethyl acetate is known to quench LiAlH4 at -10 °C, but 
addition of 2 N HCl gave lower yield, because it probably protonated the primary amine 
transforming into an aminium group ( ), which during organic/aqueous extraction 
went to the aqueous phase. 
2. EtOAc and Na2SO4∙10H2O: Addition of Na2SO4∙10H2O gave a better yield then 
the previous method (EtOAc and 2 N HCl), but four hours were required to decompose 
the LiAlH4, because with any extended time in EtOAc the solution and product would 
decompose. An overnight quenching was  expected to lower the yield. 
3. EtOAc and 3 M NaOH: Addition of 3 M NaOH gave the highest yield, but the 
amine was still sensitive to heat and decomposed upon standing in solution. 
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 Under these circumstances, the possibility to eliminate a reduction reaction using 
LiAlH4 in the reaction pathway was analyzed. Therefore, the following route was applied 
(see Scheme 35). 
 
Scheme 35: Alternative route to obtain 44. 
 
 In order to eliminate the reduction reaction of the azide group using LiAlH4, 
product 36 (DCB 3506) was used to successfully obtain 42 in an alkylation reaction. 
Then, a transformation reaction from Br to N3 was also carried out in high yield. The 
reduction of the azido group was achieved using hydrogenation under pressure (50 psi) 
using two different catalysts: Pd-C or PtO2 (Adams’ catalyst). Unfortunately, product 44 
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was still as sensitive and unstable as 40. Therefore, the next step had to be carried out 
without purification. 





In order to link biotin via a peptide bond to the primary amine 40, (HATU) or 
(HBTU) (see Figure 46) was used as a coupling reagent. Both of these coupling 
reagents were chosen because either was successful for generating the peptide bond. 
Other coupling reagents were tried, such as DCC (1,3-dicyclohexylcarbodiimide), DIC 
(diisopropylcarbodiimide), and EDC (ethyldimethylaminopropylcarbodiimide), but these 
were either unsuccessful or gave the product in low yield. 
 
 
Figure 46: Chemical structure for HBTU, DCC, DIC, and EDC. 
 
The carbodiimide activated ester is very reactive. In the case of slowly reacting 
nucleophiles, rearrangement is a common side reaction, which might have formed the 
stable acyl urea (see Scheme 36). Since the coupling reagent was left stirring overnight 
with biotin, this could be the reason for the unsuccessful reactions using DCC, DIC, and 





Scheme 36: The carbodiimide activated ester rearrangement. 
 
There exits a large number of coupling reagents, but two are more popular, 
HBTU and HATU. These analogous compound HATU and HBTU were used to form the 
peptide bond. The following reactions represent the mechanism reaction to obtain 41 in 










Scheme 38: Mechanism using HBTU. 
 
Mass spectrometry: 
1. AccuTOF-DART in either the positive- or negative-ion mode did not detect 41. 
This is expected due to the high molecular mass M = 720.356 and the presence 
of biotin. Starting material 40 was not detected either. 
2. Quatro II spectromer: The Waters Quattro II is a triple quadrupole mass 
spectrometer. The Quattro II is equipped with an electrospray-ionization (ESI) 
source and an atmospheric pressure chemical ionization (APCI) source. It is 
integrated with an Agilent 1050 HPLC system. The Quatro II detected the 41 
mass [M+1]+ = 721.214 and its ion fragment [M-OH]+ = 703.191 with high 
intensity, as seen in Figure 47 Although, it is known that the Quatro II does not 
provide high-resolution MS, it showed the expected [M+1] ion. 
3. MALDI-TOF MS: This instrument provided high-resolution, and the peaks could 
be calibrated with an internal calibration standard. MALDI detected the [M] = 
720.3385 and sodium adduct [M + Na]+ = 743.3406 with a ppm error of 6.7 ppm 
(see Figure 48), and 2.6 ppm (see Figure 49) on different occasions. According 
to our instrument specifications; the limit of error for the MALDI-TOF MS should 
not be higher than 10 ppm.  
123 
 
It is important to indicate that these spectra show higher peaks at 795.5387, 
853.5866, 911.6284, 969.6696 that belonged to the internal calibration standard that 
was mixed with 41 in order to calibrate the peaks. 
Table 13 shows the summary of molecular masses for the theoretical and experimental 
results. 
The ppm error was calculated with the following formula given by the mass 
spectroscopy center. 
Mass Accuracy 
∆m = mtheoretical - mmeasured 
ppm Error = (∆m/mtheoretical) x 10
6  
Example: 
∆m = 743.345 – 743.347 = 0.002 
ppm Error = (0.002 / 743.345) x 106 = 2.690 
 
Table 13: Theoretical and experimental mass for compound 40 
Product 41 Theoretical mass (m/z) Experimental mass (m/z) 
[M] 720.356 720.338 
[M – OH]+ 703.353 703.343 
[M + Na]+ 743.345 743.347 
 








 The crude product 41 was run on the HPLC using a reversed-phase column 
(C18). This separation indicated the number byproducts and starting materials in the 
crude product. Since the HPLC spectrum indicated at least 7 peaks, a precipitation of 
the pure product was tried using MeOH:Et2O (10:1). A yellowish solid precipitated 
overnight in the freezer.  This solid was run in the HPLC using the method Tylo 79:21 
(79% MeOH and 21% H2O) that demonstrated the best separation of peaks. The HPLC 
results showed 6 peaks (see Figure 50). Since it is a novel compound, the author did 
not know which peak belonged to product 41. In order to solve this problem, a HPLC–
MS separation was used (using the same separation method Tylo 79:21 and reversed-
phase column (C18) to find which peak belonged to product 41. Product 41 was the fifth 
peak that came out from 4.06 to 5.08 minutes (see Figure 51), with molecular weight 
[M+1]+ = 721.13. Using these important results, the next step will be used a Biotage 
instrument with reversed-phase column to separate the product 41.  





























Figure 52: Molecular modeling of the structure for compound 41. 
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CHAPTER 6: Evaluation of the Tylophorine Analogs in the 
National Cancer Institute’s screen. 
6.1 Statement of Problem 
 The goal was to have the National Cancer Institute evaluate synthetic analogs to 
DCB 3503 in their 60-cell line panel of human-derived cancer cells. Structure–activity 




The Developmental Therapeutics Program (DTP) of the National Cancer Institute 
(NCI) conducts a screening program in vitro and in vivo for potential anti-cancer 
compounds. The main purpose of this project is to identify and evaluate novel chemical 
compounds and to define, to a limited extent, their mechanism of action. 
6.2.2. In Vitro testing cells 
The In Vitro Cell Line Screening Project (IVCLSP) was developed in 1990 at the 
NCI.  This project routinely screens 60 different human tumor cell lines with subpanels 
that include the following: lung cancer, colon cancer, breast cancer, ovarian cancer, 
leukemia, renal cancer, melanoma, prostate cancer, and CNS cancer (central nervous 
system). The goal was to evaluate synthetic compounds or natural product samples to 
observe any selective growth inhibition or cell killing for any tumor cell indicated above.  
The biological results are represented by algorithms, which can be indicative of 
certain mechanisms of action from a test compound. These algorithms could indicate a 
range of compounds that might interact with specific molecular targets. Analysis of this 
data can be performed by a program called COMPARE.    
6.2.3. Concentrations parameters 
The NCI used these parameters: GI50, TGI, and LC50 mainly as algorithms to 
represent the results from each cancer cell screened. 
GI50: These data represent the drug sensitivity. In other words, GI50 indicates the 
concentrations required to inhibit cancer cell growth by 50%. The GI50 is a measure of 
the growth inhibitory power of the test agent. 
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TGI: These data signify the cytostatic effect. In other words, TGI is a measure of the 
suppression of cellular growth or multiplication. 
LC50: These data indicate the lethal concentration that kills cancer cells by 50%. 
6.2.4 The Mean Graph 
The mean graph represents the in vitro results that emphasize differential results 
on various tumor cell lines. 
The mean graph plot the positive and negative results from a set of GI50, TGI, 
and LC50 values. The vertical line represents the mean response of the cell lines. 
Positive and negative results are plotted along the vertical line. Results on the right 
represented cellular sensitivities of the cell that exceed the mean. Results on the left 
represent cell line sensitivities of the cell less than the average value. 
6.3 DCB 3503 cytotoxic analysis and structure–activity relationships  
Evaluation of DCB 3503 in the National Cancer Institute’s tumor screen showed 
a uniform and potent inhibition of cell growth in all 60 cell lines (GI50 ~ 10
-8 M) as seen in 
Figures 51 and 53, with notable selectivity toward several refractory cell lines, including 
melanoma and colon cancer cell lines based on GI50 values. 
The overall activity of DCB 3503 can be seen in Figure 50. DCB 3503 dose–
response curves (all cell lines) showed a concise drop for all cancer cells at 10-08 M. The 
direction of that curve is important, because it indicates that almost all cancer cells were 
inhibited to 50% growth at 10-08 M. It is important to indicate that DCB 3503 has the 
lowest GI50 among all our DCB analogs; therefore, it holds the highest activity. The 
following Table 14 shows some of the relevant cancer cell lines that were inhibited by 
DCB 3503. The complete table can be seen in Figures 53, 54, 55, and 56. 
Table 14: DCB 3503 some relevant cell line and growth percent 
Panel/Cell Line GI50 (E
-08) 
Colon Cancer (COLO 205) 1.00 
Renal Cancer (786-0) 1.00 
Melanoma (SK-MEL-2) 1.00 
Melanoma (SK-MEL-5) 1.00 
Additionally, Dr. Gao did additional biological testing of DCB 3503 at Yale 
University. DCB 3503 also exerted potent growth-inhibitory effects against HepG2 
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(human hepatocellular carcinoma) and KB (human nasopharyngeal carcinoma) cell 
line’s.3 
Treatment of nude mice bearing HepG2 tumor xenografts by i.p. injections of 
DCB 3503 at 6 mg/kg every 8 h on days 0 and 3 resulted in significant tumor growth 
suppression (P < 0.0001). Unlike conventional antitumor drugs, 3 μM DCB 3503 did not 
cause DNA breaks or apoptosis in HepG2 cells. 
This tylophorine analog is a member of a unique class of antitumor compounds 
that have a mode of action different from known antitumor drugs. Early mechanistic 
studies demonstrated that tylophorine analogs irreversibly inhibit protein synthesis at 
the elongation stage of the translation cycle.  The phenanthroindolizidine alkaloids 
tylophorine have been shown to be powerful inhibitors of the incorporation of leucine 
into protein in Ehrlich ascites-tumor cells (a transplantable, poorly differentiated 
malignant tumor which appeared originally as a spontaneous breast carcinoma in mice. 
It grows in both solid and ascitic forms by 50% at 10-6 M, but does not inhibit the 
incorporation of uracil into nucleic acids at 10-5 M.6 
In 1960, tylocrebine was advanced to clinical trial but failed due to its significant 
CNS toxicity, manifested as disorientation and ataxia. Dr. Staerk proposed to synthesize 
more polar analogs that could minimize the side effects, because these polar analogs 
would not pass through the blood–brain barrier. Therefore, DCB 3503 is an excellent 
candidate to overcome this problem, because it contains a secondary alcohol at C14, 
which provides polarity (see Figure 53. 
 
 














































e 57: DCB 3503 in-vitro testing results. 
140 
 
6.4 DCB 3507 cytotoxic analysis and structure–activity relationships  
Evaluation of DCB 3507 for the National Cancer Institute tumor screen showed a 
potent inhibition of cell growth in some of the cell lines with an overall GI50 ~10
-6 M, with 
notable selectivity toward several refractory cell lines in melanoma and renal cancer 
(see Table 15). 
Table 15: DCB 3507 relevant cell line, GI50, and growth percent 
Panel/Cell Line GI50 E-06 Growth Percent 
Colon Cancer (COLO 205) 1.12 -54.78 
Renal Cancer (786-0) 3.58 -56.30 
Melanoma (SK-MEL-2) 3.03 -54.67 
Melanoma (SK-MEL-5) 1.07 -70.34 
 
Even though DCB 3507 showed high activity, it has lower activity when 
compared to DCB 3503. DCB 3507 presented interesting activity with melanoma1 and 
renal cancer at GI50 = 10
-06 M, but DCB 3503 had a GI50 = 10
-08 M against the same 
tumor.  
DCB 3507 clearly showed its lower activity in the graph: dose–response curves 
(all cell lines) in Figure 57, 58, 59, 60, and 61. These graphs indicated straight inactivity 
lines from 10-08 M until 10-06 M, only after 10-06 M inhibition of cancer cells start to grow 
by an overall drop of cell lines. Due to this lower activity any further analysis or 
modification for DCB 3507 has been teminated. 
Although DCB 3507 had low reactivity, it gave positive and conclusive structure–
activity relationship (SAR) results.  
First: The DCB 3503 analog must have at least four methoxy groups to increase 
biological activity. The exact positions could be in R2, R3 for the top part of the 
phenanthrene ring, and R5,R6 or R6,R7 for the bottom part of the aromatic system as 
seen in Figure 58. The possibility to increase activity in R5, R6 analog instead of an 
analog substituted in the R6, R7 position was indicated by tylocrebine’s high activity, 
because it had the methoxy groups in R5, R6 position. However, little is known about 
the precise mode of action of these compounds, and similar structures may not have 
similar modes of action, a point recently made in the study by Y.-C. Cheng and co-
workers. So far, we had used methoxy groups, but it would be interesting to make 
ethoxy groups or long/short aliphatic chains with polar functional groups at the end 
141 
 
replacing methoxy groups to study their biological activities. Therefore, DCB 3508 has 
been synthesized. 
It is likely that the ring’s electron density affects the binding at the indolizidine 
system, which is more likely the pharmacophore. 
It is important to indicate that all these biological data are investigation about potency, 
but these data gave limited information on any results any adverse effects. At this time, 
we do not know if DCB 3503 is more toxic in vivo or is able to produce more negative 
side effects in the human body than DCB 3507. Our main goal is both to increase 
potency and decrease adverse effects, such as addictive properties. 
 
 























Figure 63: DCB 3507 mean graphs. 
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6.5 DCB 3508 cytotoxic analysis and structure–activity relationships  
Evaluation of DCB 3508 in the National Cancer Institute tumor screen did not 
show potent inhibition of cell growth in the cell lines (GI50 ~10
-5 M) (see figure 64) with 
an interesting selectivity toward several refractory cell lines in leukemia, (see Table 16). 
 
Table 16: DCB 3508 relevant cell line and growth percent 
Panel/Cell Line Growth Percent 
Leukemia (MOLT-4) -46.10 
Leukemia (SR) -50.57 
Renal Cancer (ACHN) -50.09 
Renal Cancer (SN12C) -49.37 
Melanoma (LOX IMVI) -46.03 
 
This low reactivity allowed one draw certain conclusions about structure–activity 
relationships (SAR). 
First: the tylophorine system must be complete and have a closed cyclohexyl ring (see 
Scheme 42) in order to be active (GI50 , 10-6 M, for example).  
 
 





Second: there may be a configurational dependence at C14 for anticancer activity.  The 
(S)-epimer (DCB 3503) is more active than the (R)-epimer (DCB 3501), and the activity 
of DCB 3507, whose-OH group is relatively free to rotate and assume a variety of 
conformations, is further diminished. 
Given the fast that the 14-OH group in DCB 3503 increases in vivo activity over 
that of tylophorine (DCB 3500), which lacks a C14 hydroxy group. 
The 14-OH could be modified by its bioisosteres, that is functional groups with 
similar chemical activity and as consequence similar biological activity. The possible 
bioesteres are CH3, NH2, F, and Cl.
36 The chiral C14 carbon with stereochemistry (S) 
sould not be modified, because it was proven that (S) chiral was more active than (R). 








Figure 65: DCB 3508 One–dose mean graph. 
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6.6 DCB 3509 cytotoxic analysis and structure–activity relationships.  
 The biological activity of DCB 3509 will be obtained from NCI within 3-4 months. 
The potency has been predicted to be high by the CoMFA molecular modeling program, 
using structures and biological data from DCB 3503, DCB 3507, and DCB 3508. These 
considerations, the author decided to synthesize DCB 3509 with a short saturated 
straight chain of three carbons with a polar hydroxyl group at the end (see Figure 66). 
The length of the chain will be varied if DCB 3509 turns out to be highly active. 
 
 




6.7 Synthesis of biotinylated tylophorine analog cytotoxic analysis 
and structure–activity relationship  
 The biological activity of this biotinylated tylophorine analog will be available in a 




 The improved synthesis of DCB 3503 has provided the means to produce DCB 
3503 in 200–400 mg amount in one batch, which in the past was limited to 60 mg in one 
batch. The most expensive chemicals were replaced with cheaper reagents that were 
commercially available. These reactions gave also higher yields and were suitable for at 
least a 4 g scale. These new reactions or improved steps eliminated the need to run 
chromatography columns to purify products; therefore, the use of expensive solvents 
such as EtOAc and hexanes were not needed to purify scale-up reactions up to 4 g.  
The syntheses of DCB 3503, DCB 3506, DCB 3507, DCB 3508, DCB 3509, and 
the biotinylated chain to DCB 3506 were carried out to develop the structure–activity 
relationships and to study the mechanism of reaction with tumor cells. We were also 
interested in pharmacokinetic, and pharmacodynamics in the cellular level to identify the 
pharmacophore that binds to cancer cells. 
I. Structure–Activity Relationships. 
All compounds were evaluated in the 60-cell panel of human-derived tumor cells 
at the National Cancer Institute. These results offered important information about their 
structure–activity relationships (SAR). These analogs were modified by replacing 
methoxy groups (DCB 3503) with hydrogen (DCB 3507), opening cyclic rings (DCB 
3508), and attaching a short aliphatic chain (DCB 3509). These modifications either 
increased or lowered activity.  
Tylophorine is considered a structurally specific drug. These drugs, which most 
drugs are, act with specific sites such as a protein receptor or enzyme. Tylophorine’s 
activity and potency was shown to be susceptible to small changes in chemical 
structure. Therefore, changing chemical groups gave us an idea what groups were 
responsible for evoking a biological effect in the living organism.  
II. Pharmacokinetics. 
It is known that more than three-quarters of drug candidates do not make it to 
clinical trials because of problems with pharmacokinetics in animals.37 Only less than 
10% of drug candidates in clinical trials become marketed products. One of the main 
obstacles is pharmacokinetic problems, which manifest themselves as poor oral 
bioavailability or short plasma half-life. Low water solubility of a compound (high 
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lipophilicity) is a limiting factor in oral bioavailability, and highly lipophilic compounds are 
easily metabolized or tend to bind to plasma proteins. Moreover, low lipophilicity leads 
to poor permeability through membranes. Therefore, we need to balance the 
pharmacokinetic properties of the tylophorine analogs to modify and increase potency. 
Pharmacokinetics is important for drug discovery, and in 1997 Lipinski proposed 
“the rule of five” as guide to improve oral bioavailability during modifications. It has been 
shown that more than 90% of the compounds with two or more of these points will have 
poor oral absorption or distribution properties: 
1. Molecular weight is >500. 
2. The log P is < 5. 
3. There are more than 5 H-bond donors. 











Table 17: Lipinski’s “rule of five” applied to DCB analogs 
 
 DCB 3503 DCB 3507 DCB 3508 DCB 3509 
Molecular weight 409.189 349.168 453.215 411.205 
Log P 2.92 3.18 2.51 3.24 
5 H-bond donors 1 1 1 2 






Analysis of Lipinski’s “rule of five” applied to DCBs can be seen in Table 17. The 
molecular weight for DCB 3503, 3507 3508, and 3509 are all below 500. As mentioned 
before, the side chain of DCB 3509 could be increased up to 6 carbons and its 
molecular weight would still below 500.  
Log P values, the partition coefficients, for all tylophorine analogs are below 5. 
The partition coefficient is useful to estimate distribution of drugs within the body.  
The number of H-bond donors is expressed as the sum of OH and NH. All our 
tylophorine analogs contained less than 2. The number of H-acceptors is expressed as 
the sum of N and O. All our tylophorine analogs are below 7. As result, all tylophorine 
analogs would pass the Lipinski’s rule of five, which predicts a good oral absorption. 
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Chapter seven: Experimental 
Experimental procedure to scale-up DCB 3503 
General Methods 
All reactions were monitored using thin-layer chromatography (TLC).  Absorption 
chromatography was carried out using Sorbent Technologies silica gel plates with a 200 
mm thickness. All NMR spectroscopy was used the Varian 300 MHz NMR. Melting 
points were determined on a Thomas-Hoover capillary melting point apparatus. 
Positive-ion electrospray mass spectra were acquired on Accutof DART, MALDI, and 
QUATRO-II quadrupole instrument. 
Preparation of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid  (3).  
3,4-Dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol) was stirred in Ac2O (55 mL) 
and TEA (40 mL) until solution was completely dissolved, then (3,4-
dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was 
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room 
temperature, and water (50 mL) was added dropwise. An increase in temperature was 
expected, so addition of water was stopped momentarily until temperature dropped to 
room temperature. Then, a solution of K2CO3 (75 g) in water (250 mL) was added 
dropwise. From experience, it is recommended to stop adding the K2CO3 solution 
momentarily if formation of sticky oily brown substance started to appear on the walls 
and bottom of the beaker; then, continue adding K2CO3 solution dropwise. If formation 
of sticky substance was formed and stopped the stir bar, then the solution must be left 
stand for 30-60 minutes at room temperature until it turned solid and stir bar was again 
able to spin. The mixture was refluxed until all solids dissolved. Then, mixture was 
cooled to room temperature and left spinning overnight. Mixture was separated with 
Et2O (2 x 100 mL) and aqueous phase was collected (bottom). The aqueous layer was 
acidified with 2 N HCl, which was added dropwise until pH 1 was reached. If a sticky 
substance is formed, then the mixture must be left spinning for 30-60 minutes at room 
temperature, at which time all should solidify; acidification was then continued. The 
precipitation was recrystallized using MeOH to obtain 35.0 g of 3 (>90.0 % yield).  mp: 
208 °C. 1H NMR (CDCl3): δ 3.46 (3H, s), 3.80 (3H, s), 3.83 (3H, s), 3. 88 (3H, s), 6.54 
(1H, s), 6.73 (1H, d), 6.78 (1H, s), 6.81 (1H, d), 6.84 (1H, d), 6.9 (1H, d), 7.83 (1H, d); 
157 
 
13C (NMR CDCl3): δ 55.42, 55.90, 55.92, 56.08, 111.83, 112.65, 112.85, 116.80, 
116.82, 142.52. EIMS calcd for C19H20O6 m/z 344.13; found 345.126 
Preparation of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4) 
To a solution of compound 3 (13.0 g, 37.77 mmol) in MeOH (500 mL) stirred at 60 °C 
was added dropwise H2SO4 (15 mL) and the solution was stirred overnight under reflux. 
The mixture was concentrated by rotary evaporation at 35-40 °C ( do not heat above 50 
°C lest a purple oily product form) and a liquid-solid residue formed. This crude product 
was filtrated and washed quickly with cold MeOH. This solid was purified by column 
chromatography (2:0.5 EtOAc:hexane), but most of the time it was not necessary. Yield: 
13.05 g of 4 (>90%) mp: 125 °C. 1HNMR (CDCl3): δ 3.49 (3H, s), 3.80 (3H, s), 3.82 (3H, 
s), 3.85 (3H, s), 3.90 (3H, s), 6.53 (1H, s), 6.73 (1H, m), 6.81 (1H, m), 6.84 (1H, m), 
6.78 (1H, m), 6.90 (1H, m), 7.70 (1H, s); 13C NMR (CDCl3): δ 52.59, 55.42, 55.92, 56.00, 
56.08, 110.49, 111.49, 112.49, 112. 98, 122.43, 125.43, 140.53. EIMS calcd for 
C20H22O6 m/z 348.14; found 349.136 
Preparation of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (5) 
Method A: Using FeCl3 
A solution of compound 4 (4.0 g, 11.17 mmol) in DCM (250 mL) was cooled to - 10°C. 
Then a solution of anhydride FeCl3 (13 g, 80.83 mmol) in EtOAc (250 mL) was added 
dropwise. The solution was stirred overnight, but the reaction was completed as soon 
as FeCl3/EtOAc solution was added. The TLC was used to confirm completion of the 
reaction (2:0.5 EtOAc:hexanes). The product’s spot must be bright blue with spray/heat 
development with anisaldehyde-sulfuric acid. † The presence of a small brown spot on 
the TLC plate (spots of product and starting material overlap), is indicative of the 
presence of starting material. If this is the case, then the temperature of the solution 
was lowered using an ice bath at -10 °C and a solution of FeCl3 anhydride in EtOAc was 
added, the amount depending on the size of the brown spot. To quench the reaction, 
water (250 mL) was added to the solution and mixture was allowed to stir for 3 hours or 
until it turned dark yellow, if the solution had a dark green color, then more water was be 
added. The solution was extracted with CHCl3 (3 x 50 mL) and dried with Na2SO4. The 
mixture was filtered and solvent was evaporated at ≤ 35 °C, because the final 
compound is heat sensitive. The crude product was purified by column chromatography 
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(2:0.5 EtOAc:hexanes) to give 3.86 g 5 (>90%) mp. . 1HNMR (CDCl3): δ 4.01 (1H, s), 
4.04 (1H, s), 4.07 (1H, s), 4.12 (1H, s), 4.14 (1H, s), 7.27 (1H, s), 7.77 (1H, s), 7.80 (1H, 
s), 8.42 (1H, s), 8.65 (1H, s); 13(CDCl3): δ 52.26, 52.5, 56.08, 56.09, 56.25, 56.26, 
102.70, 102.87, 107.02, 109.50. EIMS calcd for C20H20O6 m/z 356.13; found 357.132 
Method: VOF3 
To a compound 4 (1.86, 5.19 mmol) was added DCM (18 mL), and mixture was stirred 
at -10 °C. Then, a solution of VOF3 (2 g, 16.14 mmol), DCM (35 mL), EtOAc (17.5 mL), 
TFA (1 mL), and TFAA (3 drops) was added dropwise with stirring. The solution was 
stirred for 5 h at -10 °C. To quench the reaction, the mixture was poured onto ice and 
extracted with CHCl3 (3 x 50 mL). The organic phase was dried with Na2SO4 and 
filtered, and solvent was evaporated. The crude product was purified by column 
chromatography (2:0.5 EtOAc:hexanes) to give 1.55 g (80%) of 5. TLC showed a bright 
blue color under anisaldehyde TLC stain. In our experience, VOF3 is a toxic powder that 
has to be open quickly inside a hood. The VOF3 solution stains glassware with a green 
color that can be removed with 2 N HCl. This organic waste must be disposed of in a 
separate container. 
Preparation of (2,3,6,7-tetramethoxyphenylphenanthren-9-yl)methanol (6) 
For this reduction, a three-neck round flask was outfitted to be maintained under an N2 
atmosphere. To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at - 10 °C was 
added dropwise a solution of 5 (3.95 g, 11.09 mmol) in THF. Ice bath was removed, and 
the mixture was stirred at room temperature overnight. The mixture was again cooled to 
-10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g) 
was added slowly until solution stopped bubbling and turned yellow. The mixture was 
stirred overnight. Alternatively, 2 N HCl can be used instead of Na2SO4·10H2O to 
quench the reaction, but lower yield generally resulted. The mixture was filtered, and the 
solvent was evaporated by rotary evaporation. The crude product was purified by 
column chromatography (2:0.5 EtOAc:hexanes) to give 3.18 g 6 (>90%) mp: 184 ° C. 
1HNMR (CDCl3): δ 4.03 (3H, s), 4.07 (3H, s), 4.12 (3H, s), 4.14 (3H, s), 5.14 (2H, s), 
7.22 (1H, s), 7.56 (1H, s), 7.60 (1H, s), 7.78 (1H, s), 7.84 (1H, s); 13C NMR (CDCl3): δ 
56.00, 56.08, 56.10, 56.25, 65.04, 103.03, 103,37, 105.02, 108.67, 124.24. EIMS calcd 
for C19H20O5 m/z 328.13; found 329.128. 
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Preparation of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (7) 
This reaction required three steps: 
Step 1: A solution of compound 6 (3.4 g, 10.35 mmol) in freshly distilled CHCl3 (200 mL) 
was cooled to -10 °C. (Using non-distilled CHCl3 increased side reactions). Then a 
solution of PBr3 (4.8 mL, 17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath 
was removed and solution was stirred at room temperature for 1.5 h. Then, the solution 
was poured over ice and stirred until ice was completely melted. The product was 
extracted with CHCl3 and dried over Na2SO4. The mixture was filtered, and solvent was 
evaporated by rotary evaporation to obtain 6.1 as a yellow solid. Mp: 184 °C. 1HNMR 
(CDCl3): δ4.02 (3H, s), 4.11 (3H, s), 4.12 (3H, s), 4.13 (3H, s), 4.99 (2H, s), 7.52 (1H, s), 
7.67 (1H, s), 7.76 (1H, s), 7.18 (1H, s), 7.83 (1H, s); 13C NMR (CDCl3): δ 56.01, 56.05, 
56.07, 56.08, 33.85, 102.87, 103.53, 105.02, 108.50.  
Step 2: The crude product 6.1 was added DMF (200 mL), glutamic acid dimethyl ester 
27 (6 g, 28.35 mmol) and allowed to dissolve completely. Then K2CO3 (10 g) was 
added, and the mixture was stirred at 65 °C overnight. At higher or lower temperature, 
side reactions were noted.  
Step 3: The solvent was evaporated by high vacuum (~ 1 torr) rotary evaporation. The 
residue was extracted with CHCl3, and the extract was washed with water and dried 
with Na2SO4. The organic extract was filtered, and solvent was removed by rotary 
evaporation. The crude product was dissolved in MeOH (80 mL) and AcOH (80 mL) and 
stirred at 45 °C overnight. At higher or lower temperature, side reactions were formed. 
The solvent was removed by rotary evaporation, then high-vacuum rotary evaporation 
(~ 1 torr) to obtain a yellow solid. The crude product was purified by column 
chromatography (2:0.5 EtOAc:hexanes) to give 3.4 g of 7 (>90 % yield). 1HNMR 
(CDCl3): δ 2.08 (1H, m, J = 3.22 Hz), 2.12 (1H, m, J = 3.22 Hz), 2.24 (1H, m, J = 3.22), 
2.48 (1H, m, J = 3.22 Hz), 3. 46 (3H, s), 3.84 (1H, dd, 3.23, 9.05 Hz), 4.03 (3H, s), 4.034 
(3H, s), 4.12 (3H, s), 4.13 (3H, s) 4.4 (1H, m, J = 14.58 Hz), 5.49 (1H, m, 14.58 Hz), 
7.19 (1H, s), 7.41 (1H, s), 7.61 (1H, s), 7.76 (1H, s), 7.81 (1H, s); 13C NMR (CDCl3): δ 
22.89, 24.88, 44.79, 52.43, 56.08, 56.74, 56.91, 58.73, 103.03, 103.19, 105.35, 108.34, 




carboxylic acid (8) 
Compound 7 (8.0 g, 17.65 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N 
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was 
acidified with 2 N HCl until pH 1, and extracted with CHCl3 and Et2O. Alternatively, 
phosphoric acid can be used to quench the reaction, and a precipitate was formed. The 
solvent was removed by rotary evaporation to give 8 7.4 g (80 % yield) mp 220-225 °C. 
1HNMR (CDCl3): δ 2.10 (2H, m), 2.40 (2H, m), 3.69 (1H, m), 4.30 (1H, m), 4. 00 (3H, m), 
( 4.02 (3H, s), 4.10 (3H, m), 4.12 (3H, m), 5.64 (1H, m), 7.16 (1H, s), 7.44 (1H, s), 7.59 
(1H, s), 7.74 (1H, s), 7.78 (1H, s); 13C NMR (CDCl3): δ 21.90, 24.74, 51.10, 56.00, 
56.08, 56. 41, 56.24, 67.36, 102. 87, 103.34, 104.26, 105.36, 108.51. EIMS calcd for 
C24H25NO7 m/z 439.16; found 440.179. 
Preparation of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (9) 
Method A1: TFAA and BF3·Et2O 
TFAA (4.0 mL) was added to a solution of compound 8 (0.58 g, 1.32 mmol) and 1,2-
dichloroethane (45 mL). It was noted that starting material did not dissolve in 1,2-
dichloroethane until TFAA was added. The solution was stirred at room temperature for 
1 h. Then, BF3·Et2O (4 mL) was added and solution was stirred overnight at room 
temperature. The majority of solvent was removed by rotary evaporation and DCM (50 
mL) was added slowly. Then, a solution of saturated K2CO3 in water was added 
dropwise until release of CO2 stopped and solution turned yellow from a dark green 
color. The solution was stirred overnight at room temperature (or for at least 5 hours). 
Then, the mixture was filtrated, and the organic phase was extracted with CHCl3 and 
water. The solvent was removed by rotary evaporation and purified by column 
chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 9 0.4 g as a yellow powder. If 
product became oily due to heating on the rotory evaporator, then EtOAc was added 
until the product dissolved, and small amount of hexanes were added to precipitate 
product. TLC typically showed the product as a yellow spot after it was ddeveloped in 
anisaldehyde-H2SO4 TLC stain (65 %yield) mp. 
1HNMR (CDCl3): δ 2.30 (1H, m), 2.40 
(1H, m), 2.60 (1H, m), 2.62 (1H, m), 3.51 (3H, s), 3.91 (1H, m), 3.96 (3H. s), 4.05 (3H, 
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m), 4.06 (3H, s), 4.35 (1H, s), 5.44 (1H, s), 7.09 (1H, s), 7.32 (1H, s), 7.53 (1H, s), 7.72 
(1H, s); 13C NMR (CDCl3): δ 30.07, 55.02, 55.07, 56.02, 56.06, 56.17, 56.32, 58.49, 
61.17, 102.61, 102.99, 105.22, 108.14. EIMS calcd for C24H23NO6 m/z 421.15; found 
422.157. 
Method A2: Oxalyl chloride and SnCl4 
Compound 8 (0.5 g, 11.39 mmol) was dissolved in DCM (40 mL) and (CO)Cl2 (0.4 mL, 
3.15 mmol) was added dropwise, followed by the addition of a catalytic amount of DMF 
(1-2 drops). Mixture was stirring for 1.5 h at room temperature, then, it was brought to 
35 °C and SnCl4 (0.6 mL, 2.30 mmol) was added. The mixture was stirred for 4 h under 
an N2 atmosphere at 35 °C. The reaction was cooled to room temperature and was 
added cold 2 N HCl (3.5 mL). TLC showed a yellow spot as product after it was dipped 




A solution of compound 9 (3.76 g, 4.85 mmol) in dry THF (25 mL) under an N2 
atmosphere was cooled to -10 °C. Then either K-selectride or L-selectride (1.0 M 
solution in THF) (3.1 mL, 13.95 mmol) was added, and stirred for 5 h at – 35 °C. The 
reaction was quenched by the addition of 2 N HCl (2 mL), and the product was 
partitioned between CHCl3 and water. The organic solvent was removed by rotary 
evaporation and the crude product was purified by column chromatography to give 10 
(2.95 g, 75%). TLC (2:1:0.3 CHCl3:EtOAc:MeOH) generally showed an orange/red spot 
for the product after the plate was developed with anisaldehyde-H2SO4 mp. 
1HNMR 
(CDCl3): δ 2.30 (1H, m), 2.36 (1H, m), 2.62 (1H, m), 2.63 (1H, m), 2.80 (1H, m), 3.94 
(3H, s), 3.97 (1H, m), 4.09 (3H, s), 4.11 (3H, s), 4.12 (3H, s), 4.49 (1H, m), 5.19 (1H, m), 
6. 98 (1H, s), 7.59 (1H, s), 7.75 (1H, s), 7.70 (1H, s); 13C NMR (CDCl3): δ 30.20, 32.60, 
40.02, 55.90, 56.06, 58.62, 64.69, 103.53, 103.60, 103.70, 104.46, 175.40.  EIMS calcd 
for C24H25NO6 m/z 423.17; found 424.179 




For this reduction, a three-neck round-bottom flask outfitted for an N2 atmosphere was 
used. To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added 
dropwise a solution of 10 (0.27 g, 0.638 mmol) in THF. Ice bath was removed and 
solution was stirred at room temperature overnight. The solution was brought back to -
10°C, and EtOAc (50 mL) was added dropwise, then Na2SO4·10H2O was added slowly 
until the mixture stopped bubbling and turned yellow. (The mixture should not be left 
spinning for more than 4 hours. The use of 2 N HCl to quench the reaction proved to 
lower the yield.) The solution was filtered and solvent was removed by rotary 
evaporation. The crude product was purified by column chromatography (2:1:0.5 
CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp. 
1H NMR (CDCl3): δ 1.84 (1H, 
m), 2.16 (1H, m), 2.20 (1H, m), 2.21 (1H, m), 2.82 (1H, m), 3.13 (1H, m), 3.77 (3H, s), 
3.28 (1H, m), 4.10 (3H, s), 4.11 (3H, m) 4.16 (3H, m), 6.06 (1H, s), 7.37 (1H, s), 7.59 
(1H, s), 7.89 (1H,s);  13C NMR (CDCl3): δ  23.93, 24.02, 53.29, 55.71, 55.75, 55.92, 
56.08, 64.93, 65.62, 102.2, 102.54, 102.7, 105.36. EIMS calcd for C24H27NO5 m/z 
409.19; found 410.197  
Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (BMPAC) 
(27) 
To a solution of L(+)-glutamic acid 26 (6 g, 40.80 mmol) in MeOH (300 mL) at -10 °C 
was added dropwise SOCl2 (40 mL). Then, the solution was heated at 35 °C overnight. 
Heating the solution at higher temperature produced a green or orange oil. The green 
oil worked perfectly, but the orange oil was not the product expected. Solvent was 
removed by rotary evaporation at 35 °C as yellow oil that hardened into white solid 
under vacuum overnight. 
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Experimental procedure for DCB 3503  
Preparation of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid  (3).  
3,4-Dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol) was stirred in Ac2O (55 mL) 
and TEA (40 mL) until solution was completely dissolved, then (3,4-
dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was 
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room 
temperature, and water (50 mL) was added dropwise. Then, a solution of K2CO3 (75 g) 
in water (250 mL) was added dropwise. The mixture was refluxed until all solid 
dissolved. Then, mixture was cooled to room temperature and left stirring overnight. 
Mixture was separated with Et2O (2 x 100 mL) and water phase was collected (bottom). 
The aqueous layer was acidified with 2 N HCl, which was added dropwise until pH 1 
was reached. The precipitation was recrystallized using MeOH to obtain 3 (35.0 g, 
>90.0 % yield).  mp 218 °C (lit.1 215-216 °C); 1H NMR (CDCl3): δ 3.46 (3H, s), 3.80 (3H, 
s), 3.83 (3H, s), 3. 88 (3H, s), 6.54 (1H, s), 6.73 (1H, d), 6.78 (1H, s), 6.81 (1H, d), 6.84 
(1H, d), 6.9 (1H, d), 7.83 (1H, d); 13C (NMR CDCl3): δ 55.42, 55.90, 55.92, 56.08, 
111.83, 112.65, 112.85, 116.80, 116.82, 142.52. EIMS calcd for C19H20O6 m/z 344.126; 
found 345.126. 
Preparation of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4) 
Compound 3 (13.0 g, 37.77 mmol) was added to MeOH (500 mL) and the solution was 
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise and solution was stirred 
overnight. The solvent was removed by rotary evaporation at 40 °C and a precipitate 
solid/liquid was formed. This product was filtrated and washed quickly with cold MeOH. 
This solid was purified by column chromatography (2:0.5 EtOAc:hexane). To obtain 4 
(13.05 g, >90%) mp 125 °C (lit.2 126 -127 °C). 1HNMR (CDCl3): δ 3.49 (3H, s), 3.80 (3H, 
s), 3.82 (3H, s), 3.85 (3H, s), 3.90 (3H, s), 6.53 (1H, s), 6.73 (1H, m), 6.81 (1H, m), 6.84 
(1H, m), 6.78 (1H, m), 6.90 (1H, m), 7.70 (1H, s); 13C NMR (CDCl3): δ 52.59, 55.42, 
55.92, 56.00, 56.08, 110.49, 111.49, 112.49, 112. 98, 122.43, 125.43, 140.53. EIMS 
calcd for C20H22O6 m/z 358.142; found 359.136. 




Compound 4 (4.0 g, 11.17 mmol) was added to DCM (250 mL) at -10 °C. Then a 
solution of FeCl3 anhydride (13 g, 80.83 mmol) in EtOAc (250 mL) was added dropwise 
and solution was stirred overnight. To quench the reaction, water (250 mL) was added 
to the solution and allowed to stir for three hours. The solution was extracted with CHCl3 
(3  x 50 mL) and dried with Na2SO4. The solution was filtered and solvent was removed 
by rotary evaporation. The crude product was purified by column chromatography (2:0.5 
EtOAc:hexanes) to give 5 (3.86 g, >90%) mp: 202 °C (lit.3 203-205 °C). 1HNMR 
(CDCl3): δ 4.01 (1H, s), 4.04 (1H, s), 4.07 (1H, s), 4.12 (1H, s), 4.14 (1H, s), 7.27 (1H, 
s), 7.77 (1H, s), 7.80 (1H, s), 8.42 (1H, s), 8.65 (1H, s); 13(CDCl3): δ 52.26, 52.5, 56.08, 
56.09, 56.25, 56.26, 102.70, 102.87, 107.02, 109.50. EIMS calcd for C20H20O6 m/z 
356.126; found 357.132. 
Method: VOF3 
Compound 4 (1.86, 5.19 mmol) was added DCM (18 mL) at stirred at -10 °C. Then, the 
following solution was added dropwise: VOF3 (2 g, 16.14 mmol), DCM (35 mL), EtOAc 
(17.5 mL), TFA (1 mL), and TFAA (3 drops). The solution was stirred for 5 h at -10 °C. 
To quench the reaction, it was poured on ice and organic phase separated with CHCl3 
(3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was removed by 
rotary evaporation. The crude product was purified by column chromatography (2:0.5 
EtOAc:hexanes) to give  5 (1.55 g, >90%) mp: 202 °C (lit.3 203-205 °C). VOF3 stains 
glassware with a green color that can be removed with 2 N HCl.  
Preparation of (2,3,6,7-tetramethoxyphenylphenanthren-9-yl)methanol (6) 
To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at -10 °C was added 
dropwise a solution of 5 (3.95 g, 11.09 mmol) in THF. Ice bath was removed and 
solution was stirred at room temperature overnight. The solution was brought back to -
10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g) 
was added slowly. The solution was left stirred overnight. The solution was filtered and 
solvent was removed by rotary evaporation. The crude product was purified by column 
chromatography (2:0.5 EtOAc:hexanes) to give  6 (3.18 g, >90%) mp: 184 °C (lit.4 184-
185 °C). 1HNMR (CDCl3): δ 4.03 (3H, s), 4.07 (3H, s), 4.12 (3H, s), 4.14 (3H, s), 5.14 
(2H, s), 7.22 (1H, s), 7.56 (1H, s), 7.60 (1H, s), 7.78 (1H, s), 7.84 (1H, s); 13C NMR 
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(CDCl3): δ 56.00, 56.08, 56.10, 56.25, 65.04, 103.03, 103,37, 105.02, 108.67, 124.24. 
EIMS calcd for C19H20O5 m/z 328.131; found 329.128. 
Preparation of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (7) 
This reaction required three steps: 
Step 1: Compound 6 (3.4 g, 10.35 mmol) was added freshly distilled CHCl3 (200 mL) at 
-10 °C. Using regular CHCl3 increased side reactions. Then a solution of PBr3 (4.8 mL, 
17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath was removed and solution 
was stirred at room temperature for 1.5 h. Then, the solution was poured over ice and 
stirred until ice was completely melted. The organic phase was separated by extraction 
using CHCl3 and dried over Na2SO4. The solution was filtered and solvent was removed 
by rotary evaporation to obtain 6.1 as a yellow solid 9-(bromomethyl)-2,3,6,7-
tetramethoxyphenanthrene. 1HNMR (CDCl3): δ4.02 (3H, s), 4.11 (3H, s), 4.12 (3H, s), 
4.13 (3H, s), 4.99 (2H, s), 7.52 (1H, s), 7.67 (1H, s), 7.76 (1H, s), 7.18 (1H, s), 7.83 (1H, 
s); 13C NMR (CDCl3): δ 56.01, 56.05, 56.07, 56.08, 33.85, 102.87, 103.53, 105.02, 
108.50.  
Step 2: The crude product 6.1 was added DMF (200 mL), glutamic acid dimethyl ester 
27 (6 g, 28.35 mmol), and K2CO3 (10 g). The mixture was stirred at 65 °C overnight.  
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with 
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na2SO4, 
filtered, and solvent was removed by rotary evaporation. The crude product was 
dissolved in MeOH (80 mL) and AcOH (80 mL) and stirred at 45 °C overnight. The 
solution was removed by rotary evaporation and high vacuum rotary evaporation to 
obtain a yellow solid. The crude product was purified by column chromatography (2:0.5 
EtOAc:hexanes) to give 7 (3.4 g, >90 % yield) mp 215 °C (lit.5 210-215 °C). 1HNMR 
(CDCl3): δ 2.08 (1H, m, J = 3.22 Hz), 2.12 (1H, m, J = 3.22 Hz), 2.24 (1H, m, J = 3.22), 
2.48 (1H, m, J = 3.22 Hz), 3. 46 (3H, s), 3.84 (1H, dd, 3.23, 9.05 Hz), 4.03 (3H, s), 4.034 
(3H, s), 4.12 (3H, s), 4.13 (3H, s) 4.4 (1H, m, J = 14.58 Hz), 5.49 (1H, m, 14.58 Hz), 
7.19 (1H, s), 7.41 (1H, s), 7.61 (1H, s), 7.76 (1H, s), 7.81 (1H, s); 13C NMR (CDCl3): δ 
22.89, 24.88, 44.79, 52.43, 56.08, 56.74, 56.91, 58.73, 103.03, 103.19, 105.35, 108.34, 




carboxylic acid (8) 
Compound 7 (8.0 g, 17.65 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N 
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was 
acidified with 2 N HCl until pH = 1, and extracted with CHCl3 and Et2O. The solvent was 
removed by rotary evaporation to give 8 (7.4 g, 80 % yield) mp: 290-300 °C (lit.5 300-
302 °C). 1HNMR (CDCl3): δ 2.10 (2H, m), 2.40 (2H, m), 3.69 (1H, m), 4.30 (1H, m), 4. 00 
(3H, m), ( 4.02 (3H, s), 4.10 (3H, m), 4.12 (3H, m), 5.64 (1H, m), 7.16 (1H, s), 7.44 (1H, 
s), 7.59 (1H, s), 7.74 (1H, s), 7.78 (1H, s); 13C NMR (CDCl3): δ 21.90, 24.74, 51.10, 
56.00, 56.08, 56. 41, 56.24, 67.36, 102. 87, 103.34, 104.26, 105.36, 108.51. EIMS calcd 
for C24H25NO7 m/z 439.163; found 440.179. 
 
 
Preparation of (S)-2,3,6,7-tetramethoxy-13,13a dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (9) 
Method TFAA and BF3·Et2O 
TFAA (4.0 mL) was added to a solution of compound 8 (0.58 g, 1.32 mmol) and 1,2-
dichloroethane (45 mL). The solution was stirred at room temperature for 1 h. Then, 
BF3·Et2O (4 mL) was added and solution was stirred overnight at room temperature. 
Majority of solvent was removed by rotary evaporation and DCM (50 mL) was added 
slowly. Then, a solution of saturated K2CO3 in water was added dropwise. The solution 
was stirred overnight at room temperature. Then, it was filtrated and organic phase was 
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and 
purified by column chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 9 (0.4 g, 65 % 
yield) mp 225 °C (lit.5 228-230 °C). 1HNMR (CDCl3): δ 2.30 (1H, m), 2.40 (1H, m), 2.60 
(1H, m), 2.62 (1H, m), 3.51 (3H, s), 3.91 (1H, m), 3.96 (3H. s), 4.05 (3H, m), 4.06 (3H, 
s), 4.35 (1H, s), 5.44 (1H, s), 7.09 (1H, s), 7.32 (1H, s), 7.53 (1H, s), 7.72 (1H, s); 13C 
NMR (CDCl3): δ 30.07, 55.02, 55.07, 56.02, 56.06, 56.17, 56.32, 58.49, 61.17, 102.61, 
102.99, 105.22, 108.14. EIMS calcd for C24H23NO6 m/z 421.153; found 422.157. 
Method Oxalyl chloride and SnCl4 
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Compound 8 (0.5 g, 11.39 mmol) was dissolved in DCM (40 mL) and (CO)2Cl2 (0.4 mL, 
3.15 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at 
room temperature. Then, it was brought to 35 °C, to add SnCl4 (0.6 mL, 2.30 mmol) for 
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added 
cold 2 N HCl (3.5 mL). The solution was extracted withCHCl3 and H2O. The organic 
phase was separated and dried with Na2SO4, filtered, and solvent removed by rotary 
evaporation. Crude product was purified by column chromatography (2:1:0.3 
CHCl3:EtOAc:MeOH) to give 9 0.35 g. (60-75 % yield) mp 225 °C. 
Preparation of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (10) 
Compound 9 (3.76 g, 4.85 mmol) was added THF (25 mL) under N2 gas at -10 °C. Then 
K-selectride (1.0 M solution in tetrahydrofuran) (3.1 mL, 13.95 mmol) was added and 
stirred for 5 h. The solution was added 2 N HCl (2 mL). Then, organic phase was 
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and 
purified by column chromatography. (2:1:0.3 CHCl3:EtOAc:MeOH) to give 10 (2.95 g, 75 
% yield) mp 260 °C (lit.5 262 °C). 1HNMR (CDCl3): δ 2.30 (1H, m), 2.36 (1H, m), 2.62 
(1H, m), 2.63 (1H, m), 2.80 (1H, m), 3.94 (3H, s), 3.97 (1H, m), 4.09 (3H, s), 4.11 (3H, 
s), 4.12 (3H, s), 4.49 (1H, m), 5.19 (1H, m), 6. 98 (1H, s), 7.59 (1H, s), 7.75 (1H, s), 7.70 
(1H, s); 13C NMR (CDCl3): δ 30.20, 32.60, 40.02, 55.90, 56.06, 58.62, 64.69, 103.53, 
103.60, 103.70, 104.46, 175.40.  EIMS calcd for C24H25NO6 m/z 423.168; found 
424.179. 
Preparation of (13aS, 14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-13-ol (11) 
To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added dropwise 
a solution of 10 (0.27 g, 0.638 mmol) in THF. Ice bath was removed and solution was 
stirred at room temperature overnight. The solution was brought back to -10°C and 
EtOAc (50 mL) was added dropwise, then Na2SO4·10H2O was added. The use of 2 N 
HCl to quench the reaction proved to lower the yield. The solution was filtered and 
solvent was removed by rotary evaporation. The crude product was purified by column 
chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp 268 °C 
(lit.5 270 °C). 1H NMR (CDCl3): δ 1.84 (1H, m), 2.16 (1H, m), 2.20 (1H, m), 2.21 (1H, m), 
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2.82 (1H, m), 3.13 (1H, m), 3.77 (3H, s), 3.28 (1H, m), 4.10 (3H, s), 4.11 (3H, m) 4.16 
(3H, m), 4.81 (1H,s), 6.06 (1H, s), 7.37 (1H, s), 7.59 (1H, s), 7.89 (1H,s);  13C NMR 
(CDCl3): δ 23.93, 24.02, 53.29, 55.71, 55.75, 55.92, 56.08, 64.93, 65.62, 102.2, 102.54, 
102.7, 105.36. EIMS calcd for C24H27NO5 m/z 409.189; found 410.189. 
Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (BMPAC) 
(27) 
To a solution of L(+)-glutamic acid 26 (6 g, 40.80 mmol) in MeOH (300 mL) at -10 °C 
was added dropwise SOCl2 (40 mL). Then, the solution was heated at 35 °C overnight. 
Solvent was removed by rotary evaporation at 35 °C as yellow oil. A white precipitate 
was formed in vacuum overnight. 
 
Preparation of anisaldehyde TLC stain 
This clear stain was prepared by dissolving p-anisaldehyde (9.2 mL) in EtOH (338 mL) 
containing conc. H2SO4 (12.5 mL) and acetic acid (3.75 mL).  The plate was developed 
by heating on a hot plate/drier.   
169 
 
Experimental procedure for DCB 3507 
Synthesis of (E)-3-(3,4-dimethoxyphenyl)-2-phenylacrylic acid (13) 
3,4-dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol)  was stirred in Ac2O (55 mL) 
and TEA (40 mL), then 2-phenylacetic acid 12 (20.0 g, 147.0 mmol) was added. The 
solution was heated to 100 °C and left stirring overnight. The mixture was cooled to 
room temperature and water (50 mL) was added dropwise. Then, a solution of K2CO3 
(75 g) in water (250 mL) was added dropwise. The solution was refluxed until all solid 
dissolved and left spinning overnight at room temperature. The mixture was separated 
with Et2O (2 x 100 mL) and water phase was collected. The aqueous layer was acidified 
with 2 N HCl until pH = 1 was reached. The precipitation was recrystallized using MeOH 
to obtain 13 (35.0 g, >90.0 % yield).  mp 220 °C.1HNMR (CDCl3):  δ 3.36 (3H, s), 3.84 
(3H, s), 6.41 (1H, s), 6.74 (1H, d), 6.88 (1H, d), 7.29 (1H, m), 7.34 (1H, m), 7.39 (1H, 
m), 7.42 (1H, d), 7.81 (1H, s); 13C NMR (CDCl3): δ 55.25, 55.91, 110.83, 112.32, 126.26, 
128.25, 129.08, 130.24, 130.26, 142.68, 172.89. EIMS calcd for C17H16O4 m/z 284.105; 
found 285.111. 
Synthesis of (E)-methyl 3-(3,4-dimethoxyphenyl)-2-phenylacrylate (14) 
Compound 13 (13.0 g, 45.76 mmol) was added MeOH (500 mL) and the solution was 
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise, and solution was stirred 
overnight. The solvent was removed by rotary evaporation at 35 °C and a precipitate 
formed. This product was washed with cold MeOH. The precipitate was purified by 
column chromatography (2:0.5 EtOAc:hexane). To obtain 14 (13.05 g, >90%) mp 160 
°C. 1HNMR (CDCl3): δ 3.50 (3H, s), 3.82 (3H, s), 3.90 (3H, s), 5.74 (1H, d),  6.48 (1H, 
d), 6.77 (1H, d), 6.79 (1H, t), 6.83 (1H, t), 6.91 (1H, t), 6.93 (1H, d), 7.26 (1H, s), 7.75 
(1H, s); 13C NMR (CDCl3): δ 52.30, 55.34, 55.92, 111.48, 112.04, 114. 06, 122.21, 
126.97, 140.56, 145.84, 148.56, 149.27. EIMS calcd for C18H18O4 m/z 298.121; found 
299.123. 
Synthesis of methyl 2,3-dimethoxyphenanthrene-9-carboxylate (15) 
Method FeCl3 and SiO2  
Compound 14 (3.2 g, 10.73 mmol) was added DCM (320 mL) at room temperature. 
Then, a fresh mixture of FeCl3:SiO2 (11 g: 11 g) was added to the solution to be ran for 
two days at room temperature. The solution was filtered and mixture was separated with 
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CHCl3. The solvent was removed by rotary evaporation at 35 °C. SiO2 was dried 
overnight to obtain higher yield. This product was purified by column chromatography 
(2:0.5 EtOAc:hexane). To obtain 15 as a yellow powder (1.43 g, >90%) mp 128 °C. 
1HNMR (CDCl3): δ 4.03 (3H, s), 4.05 (3H, s), 4.14 (3H, s), 7.25 (1H, d), 7.62 (1H, t), 
7.64 (1H, t), 7.98 (1, s), 8.44 (1H, s), 8.55 (1H, s), 8.99 (1H, d); ); 13C NMR (CDCl3): δ 
52.13, 55.98, 56.05, 103.04, 109.21, 126.44, 126. 54,126. 69, 130.03, 168.13. EIMS 
calcd for C18H16O4 m/z 296.105; found 297.086. 
Method VOF3 and TFA 
Compound 14 (2.5, 8.38 mmol) was added DCM (35 mL) and stirred at -10 °C. Then, 
the following solution was added dropwise: VOF3 (2.5 g, 20.17 mmol), DCM (58 mL), 
EtOAc (35 mL), TFA (2 mL), and TFAA (3 drops). The solution was stirred for 5 h at -10 
°C. To quench the reaction, it was poured on ice and organic phase separated with 
CHCl3 (3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was 
removed by rotary evaporation. The crude product was purified by column 
chromatography (2:0.5 EtOAc:hexanes) to obtain 15 as a yellow powder (3.07 g, > 
90%) mp 128 °C. EIMS calcd for C18H16O4 m/z 296.105; found 297.106. 
Synthesis of (2,3-dimethoxyphenanthren-9-yl)methanol (16) 
To a mixture of LiAlH4 (0.5 g, 13.15 mmol) in THF (48 mL) at -10 °C was added 
dropwise a solution of 15 (1.2 g, 4.05 mmol) in THF. Ice bath was removed and solution 
was stirred at room temperature overnight. The solution was brought back to -10 °C and 
was added EtOAc (50 mL) dropwise, then Na2SO4·10H2O was added until solution 
turned yellow. Alternatively, 2 N HCl can be used to quench the reaction, but 
Na2SO4·10H2O gave a better yield. The solution was filtered and solvent was removed 
by rotary evaporation. The crude product was purified by column chromatography (2:0.5 
EtOAc:hexanes) to 16 as a yellow power (1.14 g, >90%) mp 150 °C. 1HNMR (CDCl3): δ 
4.05 (3H, s), 4.13 (3H, s), 5.19 (2H, s), 5.60 (1H, s), 7.71 (1H, s), 7.23 (1H, s), 7.60 (1H, 
t), 7.67 (1H, t), 8.00 (1H, s), 8.19 (1H, d), 8.60 (1H, d); 13C NMR (CDCl3): δ 64.19, 
103.53, 108.67, 122.94, 124.77, 125.27, 126.00, 126.59. EIMS calcd for C18H16O4 m/z 
268.110; found 269.109. 
Synthesis of (S)-methyl 1-((2,3-dimethoxyphenanthren-9-yl)methyl)-5-
oxopurrolidine-2-carboxylate (17)  
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Step 1: Compound 16 (1.14 g, 4.25 mmol) was added freshly distilled CHCl3 (98 mL) at 
-10°C. Then a solution of PBr3 (1 mL, 3.65 mmol) in CHCl3 (20 mL) was added 
dropwise. Iced bath was removed and solution was stirred at room temperature for 1.5 
h. Then, it was poured over ice and stirred until ice was completely melted. The organic 
phase was separated by extraction using CHCl3 and dried over Na2SO4. The solution 
was filtered and solvent was removed by rotary evaporation. 
Step 2: The crude product was added DMF (118 mL), glutamic acid dimethyl ester 27 
(3.2 g, mmol), and allowed to dissolve completely. Then K2CO3 (3.2 g) was added and 
the mixture was stirred at 65 °C overnight.  
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with 
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na2SO4, 
filtered, and solvent was removed by rotary evaporation. The crude product was 
dissolved in MeOH (63 mL) and AcOH (63 mL) and stirred at 45 °C overnight. The 
solution was removed by rotary evaporation and high vacuum rotary evaporation. The 
crude product was purified by column chromatography (2:1 EtOAc:hexanes) to give 17 
as a yellow powder (1.06 g, >90 % yield). mp 148 °C. 1HNMR (CDCl3): δ 1.94 (1H, m, J 
= 9.4 Hz), 2.07 (1H, m, J = 9.4 Hz), 2.41 (1H, m, J = 9.4 Hz), 3.76 (1H, dd, J = 2.98, 
9.15 Hz), 4.08 (3H, s), 3.99 (3H, s), 3.47 (3H, s), 4.42 (1H, d, J = 14.63 Mz), 5.47 (1H, 
d, J = 14.63 Hz), 7.09 (1H, s), 7.44 (1H, t, J = 7.9 Hz), 7.50 (1H, s), 7.56 (1H, t, J = 7.9 
Hz), 7.89 (1H, s), 8.01 (1H, t, J = 7.9 Hz), 8.5 (1H, d, J = 7.9 Hz); 13C NMR (CDCl3): δ 
22.81, 30.03, 44.47, 52.26, 52.26, 56.08, 58.74, 103.36, 108.34, 122.94, 124.93, 
126.42, 126.59, 128.58, 171.6, 172.7. EIMS calcd for C23H23NO5 m/z 393.158; found 
394.164 
 
Synthesis of (S)-1-((2, 3-dimethoxyphenanthren-9-yl)-5-oxopyrrolidine-2-
carboxylic acid (18) 
Compound 17 (1.06 g, 2.69 mmol) was stirred in solution of 1,4-dioxane (40 mL), 2 N 
KOH (25 mL), and MeOH (40 mL) for 2 h at room temperature. The solution was 
acidified with 2 N HCl until pH 1, and extracted with CHCl3 and Et2O. The solvent was 
removed by rotary evaporation to give 18 (1.04 g, >90 %) mp 160 °C. 1HNMR (CDCl3) δ 
1.90 (1H, m), 2.0 (1H, m), 2.41 (1H, m), 2.60 (1H, m), 3.8 (1H, m), 4.42 (1H, m), 5.74 
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(1H, m), 6.93 (1H, s), 7.57 (1H, s), 7.63 (1H, t), 7.67 (1H, t), 8.01 (1H, s), 8.10 (1H, d), 
8.57 (1H, d); 13C NMR (CDCl3): δ 21.05, 30.01, 41.3, 59.6, 110.2, 119.0, 121.5, 121.8, 
122.4, 122.6, 123.4, 176.4, 178.4. EIMS calcd for C22H21NO5 m/z 379.142; found 
380.150. 
Alternative method to quench reaction 18: DOWEX 50 (H+) resin 
To prepare resin: (use wet resin) 
Dovex 50 was washed with diluted 4:1 HCl:water. Then, it was washed with DI water 
until neutral. The solution RCOO- K+ was added until pH is 1-2, and resin was filtered 
off. Product was extracted and dried in rotary evaporation to obtain white powder. 
Synthesis of (S)-2,3-dimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H, 12H)-dione (19) 
Method TFAA and BF3·Et2O 
TFAA (1.5 mL) was added to a solution of compound 18 (1.32 g, 3.48 mmol) and 1,2-
dichloroethane (30 mL). The solution was stirred at room temperature for 1 h. Then, 
BF3·Et2O (1.5 mL) was added and solution was stirred overnight at room temperature. 
Majority of solvent was removed by rotary evaporation and DCM (15 mL) was added 
slowly. Then, a solution of saturated K2CO3 in water was added dropwise until release 
of CO2 stopped and solution turned yellow from a dark green color. Solution was stirred 
overnight at room temperature or at least five hours. Then it was filtrated and organic 
phase extracted with CHCl3 and water. Solvent was removed by rotary evaporation and 
purified by column chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 19 (0.93 g, 50-
70 %) mp 155 °C. 1HNMR (CDCl3) δ 2.57 (1H, m), 2.59 (1H, m), 2.60 (1H, m), 2.62 (1H, 
m), 4.09 (3H, s), 4.12 (3H, s), 4.43 (1H, m), 4.79 (1H, m), 5.86 (1H, m), 7.64 (1H, t), 
7.78 (1H, t), 7.97 (1H, s), 8.12 (1H, d), 9.03 (1H, s); 13C NMR (CDCl3): δ 20.74, 30.59, 
40.82, 61.4, 55.92, 56.08, 103.0, 107.9, 124.8, 125.0, 125.1,128.6. EIMS calculated for 
C22H21NO4 m/z 361.131, found 362.138 
Method Oxalyl chloride and SnCl4 
Compound 18 (0.5 g, 1.32 mmol) was dissolved in DCM (40 mL) and (CO)2Cl2 (0.4 mL, 
3.18 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at 
room temperature. Then, it was brought to 35 °C, to add SnCl4 (0.6 mL, 2.31 mmol) for 
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added 
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cold 2 N HCl (mL). The solution was extracted with CHCl3 and H2O. The organic phase 
was separated and dried with Na2SO4, filtered, and solvent removed by rotary 
evaporation. Crude product was purified by column chromatography (2:1:0.3 
CHCl3:EtOAc:MeOH) to give (19 g, 60-75 % yield) mp 155 °C. 
Synthesis of (13aS, 14S)-14-hydroxy-2,3-dimethoxy-12.13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (20) 
Compound 19 (0.9 g, 2.49 mmol) was added THF (26 mL) under N2 gas at -10 °C. Then 
K-selectride (1.0 M solution in tetrahydrofuran) (4.5 mL, mmol) was added and stirred 
for 5 h. Solution was added 2 N HCl (0.7 mL). Then organic phase was extracted with 
CHCl3 and water. Solvent was removed by rotary evaporation and purified by column 
chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 20 (0.47 g, >90 %) mp 118 °C. 
1H NMR (CDCl3): δ 2.30 (1H, m), 2.32 (1H,m), 2.49 (1H, J = 4,38 Hz), 2.58 (1H, m), 3.96 
(1H, m), 4.07 (3H, s), 4.08 (3H, s), 4.52 (1H, d, J = 17.49 Hz), 5.17 (1H, m), 5.42 (1H, d, 
J = 17.62 Hz), 7.52 (1H, t), 7.53 (1H, t), 7.60 (1H, s), 7.84 (1H, d), 7.93 (1H, s), 8.50 
(1H, d, J = 8.34 Hz); 13C NMR (CDCl3): δ 30.94, 31.03, 40.03, 41.01, 56.23, 56.19, 
58.47, 58.47, 65.95, 103.77, 104.47, 122.82, 123.59, 126.62,128.14. EIMS calculated 
for C22H21NO4 m/z 363.147, found 364.136 
 
Synthesis of (13aS, 14S)-2,3-dimethoxy-9,11,12,13a,14-
hexahydrodibenzo[f,g]pyrrolo[1,2-b]isoquinolin-14-ol (21) 
To a mixture of LiAlH4 (1.2 g, mmol) in THF (33 mL) at -10 °C was added dropwise a 
solution of 20 (0.47 g, 1.29 mmol) in THF. Ice bath was removed and solution was 
stirred at room temperature overnight. The solution was brought back to -10 °C and 
EtOAc (33 mL) was added dropwise, then Na2SO4·10H2O was added until solution 
turned yellow, but it should not be left spinning for more than four hours . The solution 
was filtered and solvent was removed by rotary evaporation. The crude product was 
purified by column chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 21 (0.40 g, 60-
70 %) mp 168 °C. 1H NMR (CDCl3): δ 1.75 (1H, m), 1.79 (1H, m), 1.90 (1H, m), 2.03 
(1H, m), 2.13 (1H, m, J = 4.42 Hz), 2.30 (1H, m), 2.93 (1H, d, J = 15.42 Mz), 2.95 (1H, 
m), 3.2 (1H, d, J = 15.42 Mz), 4.04 (3H, s), 4.1 (3H, s), 4.75 (1H, m, 1.78 Mz), 6.80 (1H, 
d, J = 8.12 Mz), 7.05 (1H, m, J = 7.29 Mz), 7.39 (1H, m, J = 7.34 Mz), 7.81 (1H, s), 7.87 
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(1H, s), 8.29 (1H, d, J = 8.32 Mz); ); 13C NMR (CDCl3): 21.4, 24.06, 53.43, 55.42, 55.92, 
56.25, 64.87, 103.36, 105.36, 122.28, 122.61, 125.59, 126.26. EIMS calculated for 
C22H23NO3 m/z 349.17, found 350.191. 
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Experimental procedure for DCB 3508 
Synthesis of (S)-2-(methoxycarbonyl)pyrrolidinium chloride  (23) 
To a solution of L(-)-proline 22 (4.6 g, 39.98 mmol) in MeOH (40 mL) at -30°C  was 
added SOCl2 (4 mL). The solution was heated at reflux for 1 h. Solvent was removed by 
rotary evaporation as a yellow oil and precipitate was formed in vacuum overnight. 
Synthesis of (S)-methyl 1-(2,3,6,7-tetramethoxyphenanthren-9 yl) 
methyl)pyrrolidine-2-carboxylate (24) 
To a solution of 6.1 (0.3 g, 0.77 mmol) and acetone (30 mL) was added 23 (0.2 g, 1.21 
mmol) and NaI (1g). The solution was refluxed for 48 h. Solvent was removed by rotary 
evaporation to obtain an oily compound, which was precipitated by adding EtOAc and 
hexanes (70:30 v/v) to give 24 (0.4 g, > 90%) mp 197 °C. 1H NMR (CDCl3): δ 1.18 (1H, 
m), 1.89 (1H, m), 1.68 (1H, m), 2.12 (1H, m), 2.28 (1H, m), 2.78 (1H, m), 3.19 (1H, m), 
3.53 (1H, m), 3.61 (1H, m), 4.03 (3H, s), 4.04 (3H, s), 4.05 (3H, m), 4.48 (3H, s), 4.49 
(1H, s), 7.08 (1H, s), 7.37 (1H, s), 7.68 (1H, s), 7.70 (1H, s), 8.09 (1H, s); 13C NMR 
(CDCl3): 22.89, 29.53, 51.76, 55.92, 56.18, 56.20, 56.24, 58.74, 102.86, 102.70, 
106.68, 125.43. EIMS: calcd for C25H29NO6 m/z 439.199; found 440.205. 
Synthesis of (S)-1(-((2,3,6,7-tetramethoxyphenanthren-9-yl)methylpyrrolidin-2-
yl)methanol (25) 
To a mixture of LiAlH4 (1.7g, 44. 79 mmol) in THF (100 mL) at -10 °C was added 
dropwise a solution of 24 (0.94g, 2.14 mmol) in THF. Ice bath was removed and 
solution was stirred at room temperature overnight. The solution was brought back to -
10 °C and was added EtOAc (50 mL) dropwise, then Na2SO4·10H2O was added until 
solution turned yellow. The solution was filtered and solvent was removed by rotary 
evaporation. The crude product was purified by column chromatography (2:1:0.5 
CHCl3:EtOAc:MeOH) to give 25 (0.9 g, >90 %) mp 201 °C. 
1H NMR (CDCl3): δ 1.73 
(1H,m), 1.86 (1H,m),1.89 (1H,m), 2.03 (1H,m), 2.43 (1H,m), 2.89 (1H,m), 2.92 (1H,m), 
3.49 (1H, d), 3.75 (1H, d), 3.77 (1H,m), 4.04 (3H, s), 4.08 (3H, s), 4.12 (3H, s), 4.13 (3H, 
s), 4.49 (1H, d), 7.21 (1H, s), 7.54 (1H, s), 7.61 (1H, s), 7.79 (1H, s), 7.84 (1H, s); 13C 
NMR (CDCl3): 50.77, 54.59, 55.92, 56.08, 56.22, 59.23, 62.55, 65.21, 103.3, 104.86, 
108.34, 125.76. EIMS calculated for C24H29NO5 m/z 411.205; found 412.209. 
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Experimental procedure for DCB 3506  
Synthesis of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxy)acrylic acid  
(27).  
3-hydroxy-4-methoxybenzaldehyde (26, 99+%, 15.0 g, 98.6 mmol) was stirred in Ac2O 
(55 mL) and TEA (40 mL) until solution was completely dissolved, then (3,4-
dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was 
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room 
temperature, and water (50 mL) was added dropwise. Then, a solution of K2CO3 (75 g) 
in water (250 mL) was added dropwise. The mixture was refluxed until all solid 
dissolved. Then, mixture was cooled to room temperature and left stirring overnight. 
Mixture was separated with Et2O (2 x 100 mL) and water phase was collected (bottom). 
The aqueous layer was acidified with 2 N HCl, which was added dropwise until pH 1 
was reached. The precipitation was recrystallized using MeOH to obtain 27 (39.0 g, 
>90.0 % yield).  mp 172.9 °C (lit.6 170.9-176.2 °C); 1H NMR (CDCl3): δ 2.28 (3H, s), 
3.46 (3H, s), 3.82 (3H, s), 3.89 (3H, s), 6.66 (1H, s), 6.77 (1H, m), 6.84 (1H, m), 6.89 
(1H, m), 6.90 (1H, m), 6.92 (1H, m), 7.86 (1H, s); 13C (NMR CDCl3): δ 55.42, 55.90, 
55.92, 56.08, 111.52, 112.75, 113.93, 114.20, 119.60, 142.63, 195.91. EIMS calcd for 
C20H20O7 m/z 372.121; found 373.126. 
Synthesis of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxy)acrylate 
(28) 
Compound 27 (13.0 g, 34.93 mmol) was added to MeOH (500 mL) and the solution was 
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise and solution was stirred 
overnight. The solvent was removed by rotary evaporation at 40 °C and a precipitate 
solid/liquid was formed. This product was filtrated and washed quickly with cold MeOH. 
This solid was purified by column chromatography (2:0.5 EtOAc:hexane). To obtain 28 
(12.50 g, >90%) mp 126 °C (lit.6 121.7 -123.5 °C). 1HNMR (CDCl3): δ 3.50 (3H,s), 3.79 
(3H, s), 3.82 (3H, s), 3.90 (3H, s), 6.66(1H, s), 6.76 (1H, m), 6.77 (1H, s), 6.78 (1H, m), 
6.91 (1H, m), 7.75 (1H, s), 7.87 (1H, m); 13C NMR (CDCl3): δ 55.29, 55.32, 55.90, 
111.47, 112.89, 114.09, 122.19, 126.96, 140.55, 142.63, 195.91. EIMS calcd for 
C19H20O6 m/z 344.126; found 345.122. 
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Synthesis of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-
dimethoxyyphenyl)acrylate (29) 
Compound 28 (2.5 g, 7.26 mmol) was added TEA (20 mL) and Ac2O (15 mL) and 
solution was left stirring for 1 h at room temperature. The product 29 precipitated as 
yellow powder. In case product would not precipitate, the reagents (TEA and Ac2O) 
were evaporated using high vacuum, and product was filtrated to give 29 (2.8 g, >90%) 
mp: 108 °C (lit.6 110.5-114.8 °C). 1H NMR(CDCl3): δ 2.27 (3H, s), 3.46 (1H, s), 3.80 (3H, 
s), 3.81 (3H, s), 3.89 (3H, s), 6.23 (1H, m), 6.62 (1H, m), 6.89 (1H, m), 6.88 (1H, s), 
6.90 (1H, s), 7.76 (1H, s); 13C(CHCl3):  δ 52.34, 55.34, 55.90, 55.91, 110.12, 111.43, 
113.76, 122.11, 122.16, 124.17, 140.27, 170.64. EIMS calcd for C21H22O7 m/z 386.136; 
found 387.132. 
Synthesis of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (30) 
Compound 28 (1.86, 48.17 mmol) was added DCM (18 mL) at stirred at -10 °C. Then, 
the following solution was added dropwise: VOF3 (2 g, 16.14 mmol), DCM (35 mL), 
EtOAc (17.5 mL), TFA (1 mL), and TFAA (3 drops). The solution was stirred for 5 h at -
10 °C. To quench the reaction, it was poured on ice and organic phase separated with 
CHCl3 (3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was 
removed by rotary evaporation. The crude product was purified by column 
chromatography (2:0.5 EtOAc:hexanes) to give  30 (1.55 g, >90%) mp: 122 °C (lit.6 
121.7-123.5 °C). VOF3 stains glassware with a green color that can be removed with 2 
N HCl. 1H NMR (CDCl3): δ 2.40 (3H, s), 3.96 (3H, s), 4.05 (3H, s), 4.08 (3H, s), 4.09 
(3H, s), 7.34 (1H, s), 7.76 (1H, s), 8.12 (1H, s), 8.40 (1H, s); 13C(CDCl3): δ 20.76, 52.10, 
52,18, 55.13, 55.98, 102.71, 106.70, 110.26, 116.11, 129.90. EIMS calcd for C21H20O7 
m/z 384.121; found 385.132. 
Synthesis of 9-(hydroxymethyl)-2,6,7-trimethoxyphenanthren-3-ol (31) 
To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at -10 °C was added 
dropwise a solution of 30 (3.95 g, 10.28 mmol) in THF. Ice bath was removed and 
solution was stirred at room temperature overnight. The solution was brought back to -
10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g) 
was added slowly. The solution was left stirred overnight. The solution was filtered and 
solvent was removed by rotary evaporation. The crude product was purified by column 
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chromatography (2:0.5 EtOAc:hexanes) to give  31 (3.20 g, >90%) mp: 189 °C (lit.6 
189.4-192.1 °C). 1HNMR (CDCl3): δ 4.05 (3H, s), 4.08 (3H, m), 4.09 (3H, s), 5.95 (1H, 
s), 7.11 (1H, s), 7.19 (1H, s), 7.52 (1H, s), 7.56 (1H, s), 7.84 (1H, s), 7.96 (1H, s); 13C 
NMR (CDCl3): δ 56.00, 56.10, 56.12, 63.4, 104.00, 104.70, 104.80, 109.00. EIMS calcd 
for C18H28O5 m/z 314.115; found 315.118. 
Synthesis of 1-((3-hydroxy-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-
oxopyrrolidine-2-carboxylate (32) 
This reaction required three steps: 
Step 1: Compound 31 (3.5 g, 11.14 mmol) was added freshly distilled CHCl3 (200 mL) 
at -10 °C. Using regular CHCl3 increased side reactions. Then a solution of PBr3 (4.8 
mL, 17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath was removed and 
solution was stirred at room temperature for 1.5 h. Then, the solution was poured over 
ice and stirred until ice was completely melted. The organic phase was separated by 
extraction using CHCl3 and dried over Na2SO4. The solution was filtered and solvent 
was removed by rotary evaporation to obtain the brominated intermediate as a yellow 
solid  
Step 2: The crude product intermediate was added DMF (200 mL), glutamic acid 
dimethyl ester (6 g, 28.35 mmol), and K2CO3 (10 g). The mixture was stirred at 65 °C 
overnight.  
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with 
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na2SO4, 
filtered, and solvent was removed by rotary evaporation. The crude product was 
dissolved in MeOH (80 mL) and AcOH (80 mL) and stirred at 45 °C overnight. The 
solution was removed by rotary evaporation and high vacuum rotary evaporation to 
obtain a yellow solid. The crude product was purified by column chromatography (2:0.5 
EtOAc:hexanes) to give 32 (3.8 g, >90 % yield) mp 215 °C (lit.6 210-215 °C). 1HNMR 
(CDCl3): δ 2.34 (1H, s), 2.62 (2H, m), 3.57 (3H, s), 3.82 (1H, m), 4.03 (3H, s), 4.05 (3H, 
m), 4.08 (3H, m), 4.43 (1H, d), 5.52 (1H, d), 7.16 (1H, s), 7.38 (1H, s), 7.59 (1H, s), 7.83 
(1H, s), 7.96 (1H, s); 13C NMR (CDCl3): 22.90, 29.70, 47.60, 56.00, 56.10, 56.22, 66.1, 





oxopyrrolidine-2-carboxylic acid (33) 
Compound 32 (8.0 g, 18.22 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N 
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was 
acidified with 2 N HCl until pH = 1, and extracted with CHCl3 and Et2O. The solvent was 
removed by rotary evaporation to give 33 (7.8 g, 80 % yield) mp: 318 °C (lit.6 320 °C). 
1HNMR (CDCl3): δ 2.26 (2H, m), 2.47 (2H ,m), 3.59 (1H, d), 3.85 (3H, s), 3.88 (3H, s), 
3.91 (3H, s), 4.19 (1H, d), 5.51 1H, d), 7.16 (1H, s), 7.37 (1H, s), 7.41 (1H, s), 7.74 (1H, 
s), 8.32 (1H, s); 13C NMR (CDCl3): δ 23.00, 29.94, 44.35, 56.10, 56.22, 58.57, 58.60, 
104.44, 105.51, 107.64, 109.22, 126.72, 175.89. EIMS calcd for C23H23NO7 m/z 
425.147; found 426.149. 
Synthesis of (S)-3-hydroxy-2,6,7-trimethoxy-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (34) 
Compound 33 (0.5 g, 1.18 mmol) was dissolved in DCM (40 mL) and (CO)2Cl2 (0.4 mL, 
3.15 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at 
room temperature. Then, it was brought to 35 °C, to add SnCl4 (0.6 mL, 2.30 mmol) for 
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added 
cold 2 N HCl (3.5 mL). The solution was extracted withCHCl3 and H2O. The organic 
phase was separated and dried with Na2SO4, filtered, and solvent removed by rotary 
evaporation. Crude product was purified by column chromatography (2:1:0.3 
CHCl3:EtOAc:MeOH) to give 34 0.35 g. (60-75 % yield) mp: 220 °C (lit.6 220 °C). 
1HNMR (CDCl3): δ 2.14 (2H, m), 2.39 (2H, m), 4.01 (3H, s), 4.05 (3H, s), 4.12 (3H, s), 
4.37 (1H, d), 4.67 (1H, d), 5.72 (1H, d), 7.23 (1H, s), 7.72 (1H, s), 8.09 (1H, s), 9.16 (1H, 
s); 13C NMR (CDCl3): δ 20.68, 29.64, 40.71, 55.89, 56.27, 61.07, 103.44, 103.46, 
104.39, 120.98, 195.13, 173.71. EIMS calcd for C23H21NO6 m/z 407.137; found 408.137. 
Synthesis of (13aS,14S)-3,14-dihydroxy-2,6,7-trimethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (35) 
Compound 34 (3.81 g,9.36 mmol) was added THF (25 mL) under N2 gas at -10 °C. 
Then K-selectride (1.0 M solution in tetrahydrofuran) (3.1 mL, 13.95 mmol) was added 
and stirred for 5 h. The solution was added 2 N HCl (2 mL). Then, organic phase was 
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and 
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purified by column chromatography. (2:1:0.3 CHCl3:EtOAc:MeOH) to give 35 (3.25 g, 75 
% yield) mp 160 °C (lit.6 160 °C). 1HNMR (CDCl3): δ 2.09 (2H, m), 2.28 (2H, m), 2.86 
(1H, m), 4.45 (1H, d), 5.15 (1H, d), 5.52 (1H, d), 7.17 (1H, s), 7.52 (1H, s), 7.81 (1H, s), 
7.97 (1H, s); 13C NMR (CDCl3): δ 21.72, 30.02, 45.51, 60.51, 67.55, 104.01, 104.71, 
108.81, 108.92.  EIMS calcd for C23H23NO6 m/z 409.153; found 410.155. 
Synthesis of (13aS, 14S)-2,6,7-trimethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-3,14-diol (36) 
To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added dropwise 
a solution of 35 (0.27 g, 0.66 mmol) in THF. Ice bath was removed and solution was 
stirred at room temperature overnight. The solution was brought back to -10°C and 
EtOAc (50 mL) was added dropwise, then Na2SO4·10H2O was added. The use of 2 N 
HCl to quench the reaction proved to lower the yield. The solution was filtered and 
solvent was removed by rotary evaporation. The crude product was purified by column 
chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp 168 °C 
(lit.6 170 °C). 1H NMR (CDCl3): δ 2.08 (2H, m), 2.24 (2H, m), 2.40 (1H, m), 2.47 (2H, m), 
3.40 (1H, d), 3.94 (3H, s), 3.98 (3H, s), 3.99 (3H, s), 5.13 (1H, d), 7.19 (1H, s), 7.60 (1H, 
s), 7.89 (1H, s), 8.04 (1H, s); 13C NMR (CDCl3): δ 23.03, 23.04, 53.85, 55.57, 55.66, 
55.70, 55.72, 65.80, 65.83, 103.70, 103.72, 103.86, 105.22. EIMS calcd for C23H25NO5 
m/z 395.173; found 396.173. 
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Experimental procedure for DCB 3509 
Synthesis of  (13aS, 14S)-3-(3-hydroxypropoxy)-2,6,7-trimethoxy-
9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrroolo[1,2-b]isoquinolin-14-ol (37) 
To a solution of 36 (30 mg, 75.92 μmol) in acetone (15 mL) was added 3-
bromopropanol (60 mg, 434.88 μmol) and K2CO3 (0.1 g). The solution was heated to 65 
°C for 48 hours. At room temperature, the solution was filtered and washed with CHCl3. 
The solvent was removed by rotary evaporation and concentrated to obtain an oil. The 
crude product was purified by column chromatography CHCl3:EtOAc:MeOH (2:1:0.5) to 
give 37 (30-60 mg, >90 % yield) as powder. mp 265 °C. EIMS calculated for 
























Synthesis of (13aS, 14S)-3-(6-bromohexyloxy)-14-hydroxy-2,6,7-trimethoxy-
12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (38) 
To a solution of intermediate 35 (0.07 mg, 0.17 mmol) and acetone (100 mL) was added 
1,6-dibromohexane (0.2 mL, 0.83 mmol) and K2CO3 (0.4 g). The solution was refluxed 
to 70 °C for 48 hours. At room temperature, the solution was filtered and washed with 
CHCl3. The solvent was removed by rotary evaporation and concentrated to obtain an 
oil. The crude product was added EtOAc:hexanes:Et2O (2:1:1) and left stirring for 30 
minutes, then product precipitated to give 38 (70-100 mg, >90 % yield) as yellow 
powder. mp 287 °C. 1H NMR (CDCl3): δ 1.3 (2H,m), 1.61 (2H,m),1.8 (2H,m), 1.98 
(2H,m), 2.3 (1H,m), 2.32 (1H,m), 2.5 (1H,m), 2.52 (1H,m), 2.62 (1H.m), 3.5 (2H, m), 3.8 
(3H, s), 3.91 (1H,m), 4.05 (3H,s), 4.08 (3H, s), 4.24 (2H, t), 4.43 (1H, s), 5.12 (1H,m), 
5.22 (1H,s), 6.84 (1H,s), 7.63 (1H,m), 7.71 (1H, s), 7.78 (1H, s); 13C NMR (CDCl3): δ 
28.4, 29.04, 31.69, 32.6, 32.69, 34.01, 40.1, 41.15, 56.06,56.07,56.08, 61.2, 65.87, 
69.35, 103.19, 103.37, 104.86, 105.19, 175.56. EIMS calculated for C24H29NO5 m/z 
571.157, found: 572.167, 5.74.167. 
Synthesis of 3-(6-azidohexyloxy)-14-hydroxy-2,6,7-trimethoxy-12,12,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (39)  
To a solution of intermediate 38 (30 mg, 56.15 μmol) and DMF (3 mL) was added NaN3 
(0.1g). The solution was left refluxing to 80 °C overnight. The solvent was removed by 
high vacuum evaporation. The crude product was purified by column chromatography 
(2:1:0.5) CHCl3:EtOAc:MeOH to give 39 as an oil (30-70 mg, 70 - 90 %). mp 295 °C. 
1H 
NMR (CDCl3): δ 1.30 92H,m), 1.53 (1H,m), 1.61 (1H,m), 1.69 (1H,m), 1.79 (2H,m), 1.99 
(1H,m), 2.29 (1H,m), 2.50 (1H,m), 2.59 (1H,m), 2.60 (1H,m) 2.72 (1H,m), 3.40 (2H,t), 
3.83 (1H,m), 3.92 (3H,s), 4.06 (3H,s), 4.08 (3H,s), 4.23 (2H,t), 4.43 (1H,d), 5.16 (1H,s), 
5.22 (1H,d), 6.88 (1H,s), 7.60 (1H,s), 7.69 (1H,s), 7.77 (1H,s); 13C NMR (CDCl3): δ 
19.41, 26.71, 26.72, 29.20, 31.03, 34.84, 41.15, 55.92, 56.20, 56.25, 58.57, 61.00, 
65.70, 69.19, 103.03, 103.30, 104.53, 104.86, 175.50. EIMS calcd for C29H34N4O6 m/z 





To a mixture of LiAlH4 (0.15g, 3.94 mmol) in THF (10 mL) at - 10°C was added 
dropwise a solution of 39 (50 mg, 93.59 μmol) in THF. Ice bath was removed and 
solution was stirred at room temperature overnight. The solution was brought back to –
10 °C and was added EtOAc (20 mL), H2O (10 mL), 3 M NaOH (7.5 mL), and H2O (10 
mL) dropwise. The solution was filtered with celite and solvent was removed by vacuum 
evaporation at room temperature. The crude product was used for the next step without 
any purification. The amine test using ninhydrin turned positive: purple. EIMS calculated 




A solution of biotin (0.01g, 0.04 mmol) in DMF (2 mL) under N2 gas was added HBTU 
(0.01, 0.03 mmol), and DIPEA (0.05 mL). This solution was left stirring overnight at 
room temperature. Then, intermediate 40 (0.01g, 0.02 mmol) in DMF (1 mL) was added 
dropwise. The whole solution was left stirring at room temperature overnight. DMF was 
evaporated under high vacuum pressure at room temperature, then the following 
solvents were added: MeOH: Et2O (2:10) and left in the refrigerator overnight to form a 
white precipitate. EIMS calculated for C39H52N4O7S m/z 720.36; found [M+Na]
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Chapter Two: Synthesis of DCB 3507 
 
2.2.1 Synthesis of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid  (13) 
2.2.1.1 Condensation reaction to give C 
Experimental conditions and observations in detail: 
 
Scheme 39: Condensation reaction to obtain C 
First step: the solution was left stirring until it reached room temperature. 
Second step: Water (150 mL) was added to decompose the unreacted Ac2O. The 
temperature increased quickly, so the water had to be added slowly. It could get as high 
as 60 °C.  
Third step: An aqueous solution of K2CO3 (150g/500 mL) was added, which caused 
foaming (CO2 evolution). This solid/liquid solution was reheated until reflux to ensure 
completely dissolved; then, the solution was left stirring overnight at room temperature. 
Potassium carbonate was added to eliminate water and form the alkene. Scheme  
Fourth step: The organic phase was separated with ethyl ether. The aqueous layer 
contained the cationic product. The organic layer was washed three times. 
Fifth step: The aqueous solution was quenched with concentrated HCl.  The acid was 
added dropwise with stirring. At the beginning the solution had a pH 10. As the solution 
became more acidic, it formed a sticky brown solid that stopped the stirring bar. In order 
to avoid this problem, the addition of HCl had to be slowly. A yellow precipitate started 
to form at pH 4.5–6. The addition of HCl continued until pH 1. The solution was left 
stirring overnight to maximize the conversion to product C. This precipitate was 
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separated and recrystallized with methanol at 65 °C. The final percent yield was 
between 70–80% after recrystallization. 
2.2.1.2 Condensation reaction to give (13)  
Experimental conditions and observations in detail: 
 
Scheme 40: Condensation reaction to obtain 13 
The same first, second, third, fourth, and fifth steps we repeated to synthesize 
13. The product 13 was consistently improved until a constant 95% yield. It was noticed 
that during quenching the reaction with HCl at pH ~ 5-7, a large amount of precipitate 
was formed which, seemed the right product; however, as the pH decrease to 
approximately pH 4-5, a yellowish sticky solid, formed that was unmanageable. A first 
attempt to avoid this problem to quenched at pH 5.5 and recrystallized the product. This 
white crystalline product partially dissolved in CHCl3. It was determinated that this 
product was a mixture of salts and did not give a satisfactory esterification reaction in 
the next step. 
A second attempt to overcome this problem was to add all reagents slowly. The 
first, second, and third steps were gradually carried out. Normally, it took two hours to 
complete the four steps, but in this case the addition of water and aqueous solution of 
K2CO3 were added dropwise. It took five hours for the first three steps. For the fourth 
step, the aqueous solution was quenched in an ice bath and HCl was added dropwise. 
It took two hours to decrease the pH 1. At pH 1, the solution did not form any sticky 
solid and precipitated a clean yellow product. 
As final review about this Perkin reaction, the addition of water and aqueous 
solution of K2CO3 must be added slowly. Then, the acidic quenching must be taken to 
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pH 1 with diluted HCl solution (2 N HCl), which is added dropwise to avoid the formation 
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